{"STUDYID":"PSIVISSIG0002","SUBJID":1,"USUBJID":"PSIVISSIG0002_1","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82409,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2,"USUBJID":"PSIVISSIG0002_2","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.03354,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":3,"USUBJID":"PSIVISSIG0002_3","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.31622,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":4,"USUBJID":"PSIVISSIG0002_4","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11157,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":5,"USUBJID":"PSIVISSIG0002_5","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.99863,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":6,"USUBJID":"PSIVISSIG0002_6","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.09309,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":7,"USUBJID":"PSIVISSIG0002_7","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94114,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":8,"USUBJID":"PSIVISSIG0002_8","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.3833,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":9,"USUBJID":"PSIVISSIG0002_9","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.16564,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":10,"USUBJID":"PSIVISSIG0002_10","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20671,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":11,"USUBJID":"PSIVISSIG0002_11","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.80356,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":12,"USUBJID":"PSIVISSIG0002_12","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25667,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":13,"USUBJID":"PSIVISSIG0002_13","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.13484,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":14,"USUBJID":"PSIVISSIG0002_14","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34086,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":15,"USUBJID":"PSIVISSIG0002_15","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.98973,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":16,"USUBJID":"PSIVISSIG0002_16","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.9514,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":17,"USUBJID":"PSIVISSIG0002_17","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04517,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":18,"USUBJID":"PSIVISSIG0002_18","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.01574,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":19,"USUBJID":"PSIVISSIG0002_19","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.35455,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":20,"USUBJID":"PSIVISSIG0002_20","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25667,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":21,"USUBJID":"PSIVISSIG0002_21","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84531,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":22,"USUBJID":"PSIVISSIG0002_22","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.50856,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":23,"USUBJID":"PSIVISSIG0002_23","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.60233,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":24,"USUBJID":"PSIVISSIG0002_24","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21561,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":25,"USUBJID":"PSIVISSIG0002_25","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64613,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":26,"USUBJID":"PSIVISSIG0002_26","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.99384,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":27,"USUBJID":"PSIVISSIG0002_27","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51745,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":28,"USUBJID":"PSIVISSIG0002_28","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.69473,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":29,"USUBJID":"PSIVISSIG0002_29","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.17454,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":30,"USUBJID":"PSIVISSIG0002_30","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24572,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":31,"USUBJID":"PSIVISSIG0002_31","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.80972,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":32,"USUBJID":"PSIVISSIG0002_32","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.79603,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":33,"USUBJID":"PSIVISSIG0002_33","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.31485,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":34,"USUBJID":"PSIVISSIG0002_34","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65982,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":35,"USUBJID":"PSIVISSIG0002_35","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.48323,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":36,"USUBJID":"PSIVISSIG0002_36","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.5948,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":37,"USUBJID":"PSIVISSIG0002_37","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.37919,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":38,"USUBJID":"PSIVISSIG0002_38","AGE":48,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.09309,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":39,"USUBJID":"PSIVISSIG0002_39","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.73374,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":40,"USUBJID":"PSIVISSIG0002_40","AGE":38,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.61602,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":41,"USUBJID":"PSIVISSIG0002_41","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.89596,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":42,"USUBJID":"PSIVISSIG0002_42","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54141,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":43,"USUBJID":"PSIVISSIG0002_43","AGE":89,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.46201,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":44,"USUBJID":"PSIVISSIG0002_44","AGE":80,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.61875,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":45,"USUBJID":"PSIVISSIG0002_45","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.18001,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":46,"USUBJID":"PSIVISSIG0002_46","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.42163,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":47,"USUBJID":"PSIVISSIG0002_47","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72485,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":48,"USUBJID":"PSIVISSIG0002_48","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.47091,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":49,"USUBJID":"PSIVISSIG0002_49","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.93429,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":50,"USUBJID":"PSIVISSIG0002_50","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.68309,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":51,"USUBJID":"PSIVISSIG0002_51","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19849,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":52,"USUBJID":"PSIVISSIG0002_52","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40999,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":53,"USUBJID":"PSIVISSIG0002_53","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25941,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":54,"USUBJID":"PSIVISSIG0002_54","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.19986,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":55,"USUBJID":"PSIVISSIG0002_55","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24025,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":56,"USUBJID":"PSIVISSIG0002_56","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25667,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":57,"USUBJID":"PSIVISSIG0002_57","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.6872,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":58,"USUBJID":"PSIVISSIG0002_58","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.69062,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":59,"USUBJID":"PSIVISSIG0002_59","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35592,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":60,"USUBJID":"PSIVISSIG0002_60","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17112,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":61,"USUBJID":"PSIVISSIG0002_61","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.67488,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":62,"USUBJID":"PSIVISSIG0002_62","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49966,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":63,"USUBJID":"PSIVISSIG0002_63","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51198,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":64,"USUBJID":"PSIVISSIG0002_64","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.4271,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":65,"USUBJID":"PSIVISSIG0002_65","AGE":47,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52567,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":66,"USUBJID":"PSIVISSIG0002_66","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.63723,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":67,"USUBJID":"PSIVISSIG0002_67","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67351,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":68,"USUBJID":"PSIVISSIG0002_68","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.67556,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":69,"USUBJID":"PSIVISSIG0002_69","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.92471,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":70,"USUBJID":"PSIVISSIG0002_70","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08419,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":71,"USUBJID":"PSIVISSIG0002_71","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.92676,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":72,"USUBJID":"PSIVISSIG0002_72","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.09446,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":73,"USUBJID":"PSIVISSIG0002_73","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65435,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":74,"USUBJID":"PSIVISSIG0002_74","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67625,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":75,"USUBJID":"PSIVISSIG0002_75","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.56263,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":76,"USUBJID":"PSIVISSIG0002_76","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.87269,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":77,"USUBJID":"PSIVISSIG0002_77","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.53388,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":78,"USUBJID":"PSIVISSIG0002_78","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63792,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":79,"USUBJID":"PSIVISSIG0002_79","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.43943,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":80,"USUBJID":"PSIVISSIG0002_80","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12526,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":81,"USUBJID":"PSIVISSIG0002_81","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.09172,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":82,"USUBJID":"PSIVISSIG0002_82","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.06708,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":83,"USUBJID":"PSIVISSIG0002_83","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0835,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":84,"USUBJID":"PSIVISSIG0002_84","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20397,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":85,"USUBJID":"PSIVISSIG0002_85","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65982,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":86,"USUBJID":"PSIVISSIG0002_86","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0397,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":87,"USUBJID":"PSIVISSIG0002_87","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.19644,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":88,"USUBJID":"PSIVISSIG0002_88","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56605,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":89,"USUBJID":"PSIVISSIG0002_89","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.39904,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":90,"USUBJID":"PSIVISSIG0002_90","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.60643,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":91,"USUBJID":"PSIVISSIG0002_91","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19302,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":92,"USUBJID":"PSIVISSIG0002_92","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.5729,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":93,"USUBJID":"PSIVISSIG0002_93","AGE":38,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.16632,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":94,"USUBJID":"PSIVISSIG0002_94","AGE":25,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19849,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":95,"USUBJID":"PSIVISSIG0002_95","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97331,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":96,"USUBJID":"PSIVISSIG0002_96","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12252,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":97,"USUBJID":"PSIVISSIG0002_97","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.5065,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":98,"USUBJID":"PSIVISSIG0002_98","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.29979,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":99,"USUBJID":"PSIVISSIG0002_99","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.62355,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":100,"USUBJID":"PSIVISSIG0002_100","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.36893,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":101,"USUBJID":"PSIVISSIG0002_101","AGE":87,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.15469,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":102,"USUBJID":"PSIVISSIG0002_102","AGE":83,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.87543,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":103,"USUBJID":"PSIVISSIG0002_103","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9117,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":104,"USUBJID":"PSIVISSIG0002_104","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49418,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":105,"USUBJID":"PSIVISSIG0002_105","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.80561,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":106,"USUBJID":"PSIVISSIG0002_106","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72758,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":107,"USUBJID":"PSIVISSIG0002_107","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62697,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":108,"USUBJID":"PSIVISSIG0002_108","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.34223,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":109,"USUBJID":"PSIVISSIG0002_109","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.30048,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":110,"USUBJID":"PSIVISSIG0002_110","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.0705,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":111,"USUBJID":"PSIVISSIG0002_111","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.09788,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":112,"USUBJID":"PSIVISSIG0002_112","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.83094,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":113,"USUBJID":"PSIVISSIG0002_113","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.846,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":114,"USUBJID":"PSIVISSIG0002_114","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.75359,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":115,"USUBJID":"PSIVISSIG0002_115","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.4011,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":116,"USUBJID":"PSIVISSIG0002_116","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.26078,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":117,"USUBJID":"PSIVISSIG0002_117","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36277,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":118,"USUBJID":"PSIVISSIG0002_118","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.10472,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":119,"USUBJID":"PSIVISSIG0002_119","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.01574,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":120,"USUBJID":"PSIVISSIG0002_120","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.03696,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":121,"USUBJID":"PSIVISSIG0002_121","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10883,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":122,"USUBJID":"PSIVISSIG0002_122","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11431,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":123,"USUBJID":"PSIVISSIG0002_123","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.96372,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":124,"USUBJID":"PSIVISSIG0002_124","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.74127,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":125,"USUBJID":"PSIVISSIG0002_125","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.11225,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":126,"USUBJID":"PSIVISSIG0002_126","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.88433,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":127,"USUBJID":"PSIVISSIG0002_127","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.71116,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":128,"USUBJID":"PSIVISSIG0002_128","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.3833,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":129,"USUBJID":"PSIVISSIG0002_129","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.22382,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":130,"USUBJID":"PSIVISSIG0002_130","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.86858,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":131,"USUBJID":"PSIVISSIG0002_131","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10335,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":132,"USUBJID":"PSIVISSIG0002_132","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.04038,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":133,"USUBJID":"PSIVISSIG0002_133","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28405,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":134,"USUBJID":"PSIVISSIG0002_134","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19028,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":135,"USUBJID":"PSIVISSIG0002_135","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.93771,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":136,"USUBJID":"PSIVISSIG0002_136","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.55305,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":137,"USUBJID":"PSIVISSIG0002_137","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69815,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":138,"USUBJID":"PSIVISSIG0002_138","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35044,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":139,"USUBJID":"PSIVISSIG0002_139","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.31417,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":140,"USUBJID":"PSIVISSIG0002_140","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.32307,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":141,"USUBJID":"PSIVISSIG0002_141","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.83025,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":142,"USUBJID":"PSIVISSIG0002_142","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.78713,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":143,"USUBJID":"PSIVISSIG0002_143","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04244,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":144,"USUBJID":"PSIVISSIG0002_144","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82683,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":145,"USUBJID":"PSIVISSIG0002_145","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.70431,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":146,"USUBJID":"PSIVISSIG0002_146","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.09172,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":147,"USUBJID":"PSIVISSIG0002_147","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.89254,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":148,"USUBJID":"PSIVISSIG0002_148","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82067,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":149,"USUBJID":"PSIVISSIG0002_149","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.37919,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":150,"USUBJID":"PSIVISSIG0002_150","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.95072,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":151,"USUBJID":"PSIVISSIG0002_151","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.18823,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":152,"USUBJID":"PSIVISSIG0002_152","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.10678,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":153,"USUBJID":"PSIVISSIG0002_153","AGE":92,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.94867,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":154,"USUBJID":"PSIVISSIG0002_154","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.03559,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":155,"USUBJID":"PSIVISSIG0002_155","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85147,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":156,"USUBJID":"PSIVISSIG0002_156","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.12047,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":157,"USUBJID":"PSIVISSIG0002_157","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.3833,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":158,"USUBJID":"PSIVISSIG0002_158","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.577,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":159,"USUBJID":"PSIVISSIG0002_159","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.09377,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":160,"USUBJID":"PSIVISSIG0002_160","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.20739,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":161,"USUBJID":"PSIVISSIG0002_161","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.75565,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":162,"USUBJID":"PSIVISSIG0002_162","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.55852,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":163,"USUBJID":"PSIVISSIG0002_163","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.87269,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":164,"USUBJID":"PSIVISSIG0002_164","AGE":87,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17112,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":165,"USUBJID":"PSIVISSIG0002_165","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.55989,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":166,"USUBJID":"PSIVISSIG0002_166","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.34771,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":167,"USUBJID":"PSIVISSIG0002_167","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.22108,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":168,"USUBJID":"PSIVISSIG0002_168","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.29158,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":169,"USUBJID":"PSIVISSIG0002_169","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.23614,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":170,"USUBJID":"PSIVISSIG0002_170","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.74401,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":171,"USUBJID":"PSIVISSIG0002_171","AGE":80,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72827,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":172,"USUBJID":"PSIVISSIG0002_172","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.37988,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":173,"USUBJID":"PSIVISSIG0002_173","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97194,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":174,"USUBJID":"PSIVISSIG0002_174","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19576,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":175,"USUBJID":"PSIVISSIG0002_175","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.83504,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":176,"USUBJID":"PSIVISSIG0002_176","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.07666,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":177,"USUBJID":"PSIVISSIG0002_177","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54962,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":178,"USUBJID":"PSIVISSIG0002_178","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.23888,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":179,"USUBJID":"PSIVISSIG0002_179","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.89802,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":180,"USUBJID":"PSIVISSIG0002_180","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.6653,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":181,"USUBJID":"PSIVISSIG0002_181","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.20055,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":182,"USUBJID":"PSIVISSIG0002_182","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56331,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":183,"USUBJID":"PSIVISSIG0002_183","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.94182,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":184,"USUBJID":"PSIVISSIG0002_184","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.86585,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":185,"USUBJID":"PSIVISSIG0002_185","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.57837,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":186,"USUBJID":"PSIVISSIG0002_186","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.8809,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":187,"USUBJID":"PSIVISSIG0002_187","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.16975,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":188,"USUBJID":"PSIVISSIG0002_188","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94387,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":189,"USUBJID":"PSIVISSIG0002_189","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7666,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":190,"USUBJID":"PSIVISSIG0002_190","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.59001,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":191,"USUBJID":"PSIVISSIG0002_191","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.12936,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":192,"USUBJID":"PSIVISSIG0002_192","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.64271,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":193,"USUBJID":"PSIVISSIG0002_193","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40178,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":194,"USUBJID":"PSIVISSIG0002_194","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.59069,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":195,"USUBJID":"PSIVISSIG0002_195","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.40794,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":196,"USUBJID":"PSIVISSIG0002_196","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.78234,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":197,"USUBJID":"PSIVISSIG0002_197","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.99932,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":198,"USUBJID":"PSIVISSIG0002_198","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.98289,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":199,"USUBJID":"PSIVISSIG0002_199","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87885,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":200,"USUBJID":"PSIVISSIG0002_200","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.89528,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":201,"USUBJID":"PSIVISSIG0002_201","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.4627,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":202,"USUBJID":"PSIVISSIG0002_202","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33265,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":203,"USUBJID":"PSIVISSIG0002_203","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.89254,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":204,"USUBJID":"PSIVISSIG0002_204","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.57906,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":205,"USUBJID":"PSIVISSIG0002_205","AGE":87,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.16564,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":206,"USUBJID":"PSIVISSIG0002_206","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.63518,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":207,"USUBJID":"PSIVISSIG0002_207","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.57016,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":208,"USUBJID":"PSIVISSIG0002_208","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.27858,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":209,"USUBJID":"PSIVISSIG0002_209","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.28063,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":210,"USUBJID":"PSIVISSIG0002_210","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.16632,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":211,"USUBJID":"PSIVISSIG0002_211","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.1848,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":212,"USUBJID":"PSIVISSIG0002_212","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.04312,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":213,"USUBJID":"PSIVISSIG0002_213","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.05476,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":214,"USUBJID":"PSIVISSIG0002_214","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.59069,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":215,"USUBJID":"PSIVISSIG0002_215","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.81793,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":216,"USUBJID":"PSIVISSIG0002_216","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.7269,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":217,"USUBJID":"PSIVISSIG0002_217","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.11636,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":218,"USUBJID":"PSIVISSIG0002_218","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.17728,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":219,"USUBJID":"PSIVISSIG0002_219","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.08214,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":220,"USUBJID":"PSIVISSIG0002_220","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20123,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":221,"USUBJID":"PSIVISSIG0002_221","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.06571,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":222,"USUBJID":"PSIVISSIG0002_222","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.8371,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":223,"USUBJID":"PSIVISSIG0002_223","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.2026,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":224,"USUBJID":"PSIVISSIG0002_224","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97878,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":225,"USUBJID":"PSIVISSIG0002_225","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.83094,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":226,"USUBJID":"PSIVISSIG0002_226","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.98768,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":227,"USUBJID":"PSIVISSIG0002_227","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.50582,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":228,"USUBJID":"PSIVISSIG0002_228","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.2731,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":229,"USUBJID":"PSIVISSIG0002_229","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.77139,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":230,"USUBJID":"PSIVISSIG0002_230","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00958,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":231,"USUBJID":"PSIVISSIG0002_231","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.81383,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":232,"USUBJID":"PSIVISSIG0002_232","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93634,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":233,"USUBJID":"PSIVISSIG0002_233","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69815,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":234,"USUBJID":"PSIVISSIG0002_234","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0835,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":235,"USUBJID":"PSIVISSIG0002_235","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.11362,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":236,"USUBJID":"PSIVISSIG0002_236","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.66188,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":237,"USUBJID":"PSIVISSIG0002_237","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.15264,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":238,"USUBJID":"PSIVISSIG0002_238","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.79535,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":239,"USUBJID":"PSIVISSIG0002_239","AGE":83,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.88638,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":240,"USUBJID":"PSIVISSIG0002_240","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.35934,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":241,"USUBJID":"PSIVISSIG0002_241","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.88433,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":242,"USUBJID":"PSIVISSIG0002_242","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96235,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":243,"USUBJID":"PSIVISSIG0002_243","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68172,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":244,"USUBJID":"PSIVISSIG0002_244","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68446,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":245,"USUBJID":"PSIVISSIG0002_245","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.16085,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":246,"USUBJID":"PSIVISSIG0002_246","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95551,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":247,"USUBJID":"PSIVISSIG0002_247","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.23956,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":248,"USUBJID":"PSIVISSIG0002_248","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.45722,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":249,"USUBJID":"PSIVISSIG0002_249","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.50103,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":250,"USUBJID":"PSIVISSIG0002_250","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.84463,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":251,"USUBJID":"PSIVISSIG0002_251","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.39562,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":252,"USUBJID":"PSIVISSIG0002_252","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26762,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":253,"USUBJID":"PSIVISSIG0002_253","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33949,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":254,"USUBJID":"PSIVISSIG0002_254","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20671,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":255,"USUBJID":"PSIVISSIG0002_255","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70842,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":256,"USUBJID":"PSIVISSIG0002_256","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02327,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":257,"USUBJID":"PSIVISSIG0002_257","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84805,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":258,"USUBJID":"PSIVISSIG0002_258","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82409,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":259,"USUBJID":"PSIVISSIG0002_259","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.5729,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":260,"USUBJID":"PSIVISSIG0002_260","AGE":32,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65982,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":261,"USUBJID":"PSIVISSIG0002_261","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84257,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":262,"USUBJID":"PSIVISSIG0002_262","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65982,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":263,"USUBJID":"PSIVISSIG0002_263","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.22587,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":264,"USUBJID":"PSIVISSIG0002_264","AGE":53,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61533,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":265,"USUBJID":"PSIVISSIG0002_265","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.62149,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":266,"USUBJID":"PSIVISSIG0002_266","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79398,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":267,"USUBJID":"PSIVISSIG0002_267","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.46749,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":268,"USUBJID":"PSIVISSIG0002_268","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.39014,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":269,"USUBJID":"PSIVISSIG0002_269","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72758,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":270,"USUBJID":"PSIVISSIG0002_270","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.10267,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":271,"USUBJID":"PSIVISSIG0002_271","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.83231,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":272,"USUBJID":"PSIVISSIG0002_272","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49555,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":273,"USUBJID":"PSIVISSIG0002_273","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23751,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":274,"USUBJID":"PSIVISSIG0002_274","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63792,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":275,"USUBJID":"PSIVISSIG0002_275","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.94456,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":276,"USUBJID":"PSIVISSIG0002_276","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66256,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":277,"USUBJID":"PSIVISSIG0002_277","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.65914,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":278,"USUBJID":"PSIVISSIG0002_278","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36277,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":279,"USUBJID":"PSIVISSIG0002_279","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.88433,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":280,"USUBJID":"PSIVISSIG0002_280","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04791,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":281,"USUBJID":"PSIVISSIG0002_281","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.12389,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":282,"USUBJID":"PSIVISSIG0002_282","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.91376,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":283,"USUBJID":"PSIVISSIG0002_283","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.19918,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":284,"USUBJID":"PSIVISSIG0002_284","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33402,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":285,"USUBJID":"PSIVISSIG0002_285","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.90828,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":286,"USUBJID":"PSIVISSIG0002_286","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.59959,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":287,"USUBJID":"PSIVISSIG0002_287","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61807,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":288,"USUBJID":"PSIVISSIG0002_288","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62971,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":289,"USUBJID":"PSIVISSIG0002_289","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.01232,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":290,"USUBJID":"PSIVISSIG0002_290","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.11225,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":291,"USUBJID":"PSIVISSIG0002_291","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.84052,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":292,"USUBJID":"PSIVISSIG0002_292","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.88843,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":293,"USUBJID":"PSIVISSIG0002_293","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.20808,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":294,"USUBJID":"PSIVISSIG0002_294","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33265,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":295,"USUBJID":"PSIVISSIG0002_295","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.99795,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":296,"USUBJID":"PSIVISSIG0002_296","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.98357,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":297,"USUBJID":"PSIVISSIG0002_297","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56057,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":298,"USUBJID":"PSIVISSIG0002_298","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.26626,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":299,"USUBJID":"PSIVISSIG0002_299","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.1896,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":300,"USUBJID":"PSIVISSIG0002_300","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28405,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":301,"USUBJID":"PSIVISSIG0002_301","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.19713,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":302,"USUBJID":"PSIVISSIG0002_302","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.9473,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":303,"USUBJID":"PSIVISSIG0002_303","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.5948,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":304,"USUBJID":"PSIVISSIG0002_304","AGE":39,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10883,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":305,"USUBJID":"PSIVISSIG0002_305","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65161,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":306,"USUBJID":"PSIVISSIG0002_306","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.03012,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":307,"USUBJID":"PSIVISSIG0002_307","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.76386,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":308,"USUBJID":"PSIVISSIG0002_308","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82615,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":309,"USUBJID":"PSIVISSIG0002_309","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51129,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":310,"USUBJID":"PSIVISSIG0002_310","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.4271,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":311,"USUBJID":"PSIVISSIG0002_311","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97467,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":312,"USUBJID":"PSIVISSIG0002_312","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.06297,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":313,"USUBJID":"PSIVISSIG0002_313","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.47365,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":314,"USUBJID":"PSIVISSIG0002_314","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.24572,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":315,"USUBJID":"PSIVISSIG0002_315","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.85079,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":316,"USUBJID":"PSIVISSIG0002_316","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.79329,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":317,"USUBJID":"PSIVISSIG0002_317","AGE":82,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51951,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":318,"USUBJID":"PSIVISSIG0002_318","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24025,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":319,"USUBJID":"PSIVISSIG0002_319","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40999,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":320,"USUBJID":"PSIVISSIG0002_320","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.19507,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":321,"USUBJID":"PSIVISSIG0002_321","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.29774,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":322,"USUBJID":"PSIVISSIG0002_322","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.6694,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":323,"USUBJID":"PSIVISSIG0002_323","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81725,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":324,"USUBJID":"PSIVISSIG0002_324","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04654,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":325,"USUBJID":"PSIVISSIG0002_325","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0178,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":326,"USUBJID":"PSIVISSIG0002_326","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.8371,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":327,"USUBJID":"PSIVISSIG0002_327","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.69131,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":328,"USUBJID":"PSIVISSIG0002_328","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23477,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":329,"USUBJID":"PSIVISSIG0002_329","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.70157,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":330,"USUBJID":"PSIVISSIG0002_330","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.16427,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":331,"USUBJID":"PSIVISSIG0002_331","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02053,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":332,"USUBJID":"PSIVISSIG0002_332","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.31896,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":333,"USUBJID":"PSIVISSIG0002_333","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72005,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":334,"USUBJID":"PSIVISSIG0002_334","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82067,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":335,"USUBJID":"PSIVISSIG0002_335","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.47844,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":336,"USUBJID":"PSIVISSIG0002_336","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.65092,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":337,"USUBJID":"PSIVISSIG0002_337","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.92471,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":338,"USUBJID":"PSIVISSIG0002_338","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12799,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":339,"USUBJID":"PSIVISSIG0002_339","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.10541,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":340,"USUBJID":"PSIVISSIG0002_340","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.95688,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":341,"USUBJID":"PSIVISSIG0002_341","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24572,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":342,"USUBJID":"PSIVISSIG0002_342","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.2512,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":343,"USUBJID":"PSIVISSIG0002_343","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81862,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":344,"USUBJID":"PSIVISSIG0002_344","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33676,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":345,"USUBJID":"PSIVISSIG0002_345","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.76112,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":346,"USUBJID":"PSIVISSIG0002_346","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.19644,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":347,"USUBJID":"PSIVISSIG0002_347","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.78987,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":348,"USUBJID":"PSIVISSIG0002_348","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.02669,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":349,"USUBJID":"PSIVISSIG0002_349","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.72621,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":350,"USUBJID":"PSIVISSIG0002_350","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.19781,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":351,"USUBJID":"PSIVISSIG0002_351","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.3039,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":352,"USUBJID":"PSIVISSIG0002_352","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.54825,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":353,"USUBJID":"PSIVISSIG0002_353","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.43737,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":354,"USUBJID":"PSIVISSIG0002_354","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.50992,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":355,"USUBJID":"PSIVISSIG0002_355","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.58111,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":356,"USUBJID":"PSIVISSIG0002_356","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97194,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":357,"USUBJID":"PSIVISSIG0002_357","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.91376,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":358,"USUBJID":"PSIVISSIG0002_358","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49144,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":359,"USUBJID":"PSIVISSIG0002_359","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.80972,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":360,"USUBJID":"PSIVISSIG0002_360","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49829,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":361,"USUBJID":"PSIVISSIG0002_361","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78576,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":362,"USUBJID":"PSIVISSIG0002_362","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.12183,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":363,"USUBJID":"PSIVISSIG0002_363","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.35455,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":364,"USUBJID":"PSIVISSIG0002_364","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.94045,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":365,"USUBJID":"PSIVISSIG0002_365","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.0486,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":366,"USUBJID":"PSIVISSIG0002_366","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84805,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":367,"USUBJID":"PSIVISSIG0002_367","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.8898,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":368,"USUBJID":"PSIVISSIG0002_368","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.50513,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":369,"USUBJID":"PSIVISSIG0002_369","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9692,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":370,"USUBJID":"PSIVISSIG0002_370","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19849,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":371,"USUBJID":"PSIVISSIG0002_371","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.92266,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":372,"USUBJID":"PSIVISSIG0002_372","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.90554,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":373,"USUBJID":"PSIVISSIG0002_373","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68172,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":374,"USUBJID":"PSIVISSIG0002_374","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.4668,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":375,"USUBJID":"PSIVISSIG0002_375","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.36413,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":376,"USUBJID":"PSIVISSIG0002_376","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97741,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":377,"USUBJID":"PSIVISSIG0002_377","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97194,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":378,"USUBJID":"PSIVISSIG0002_378","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.99042,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":379,"USUBJID":"PSIVISSIG0002_379","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65708,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":380,"USUBJID":"PSIVISSIG0002_380","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.60164,"CNSR":1,"EVNTDESC":"Second next-line therapy initiated","CNSDTDSC":"Censored at the end date of the next-line therapy","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":381,"USUBJID":"PSIVISSIG0002_381","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.859,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":382,"USUBJID":"PSIVISSIG0002_382","AGE":37,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.65092,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":383,"USUBJID":"PSIVISSIG0002_383","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26215,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":384,"USUBJID":"PSIVISSIG0002_384","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.3436,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":385,"USUBJID":"PSIVISSIG0002_385","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.28953,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":386,"USUBJID":"PSIVISSIG0002_386","AGE":47,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51472,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":387,"USUBJID":"PSIVISSIG0002_387","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.09651,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":388,"USUBJID":"PSIVISSIG0002_388","AGE":47,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52293,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":389,"USUBJID":"PSIVISSIG0002_389","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.26352,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":390,"USUBJID":"PSIVISSIG0002_390","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.22519,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":391,"USUBJID":"PSIVISSIG0002_391","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42094,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":392,"USUBJID":"PSIVISSIG0002_392","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49008,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":393,"USUBJID":"PSIVISSIG0002_393","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.25257,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":394,"USUBJID":"PSIVISSIG0002_394","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80219,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":395,"USUBJID":"PSIVISSIG0002_395","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28131,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":396,"USUBJID":"PSIVISSIG0002_396","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65161,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":397,"USUBJID":"PSIVISSIG0002_397","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33949,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":398,"USUBJID":"PSIVISSIG0002_398","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0835,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":399,"USUBJID":"PSIVISSIG0002_399","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.88706,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":400,"USUBJID":"PSIVISSIG0002_400","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.02738,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":401,"USUBJID":"PSIVISSIG0002_401","AGE":48,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.4271,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":402,"USUBJID":"PSIVISSIG0002_402","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.84052,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":403,"USUBJID":"PSIVISSIG0002_403","AGE":83,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.85079,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":404,"USUBJID":"PSIVISSIG0002_404","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80493,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":405,"USUBJID":"PSIVISSIG0002_405","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24298,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":406,"USUBJID":"PSIVISSIG0002_406","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.53936,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":407,"USUBJID":"PSIVISSIG0002_407","AGE":78,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34086,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":408,"USUBJID":"PSIVISSIG0002_408","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.52156,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":409,"USUBJID":"PSIVISSIG0002_409","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.7358,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":410,"USUBJID":"PSIVISSIG0002_410","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.32238,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":411,"USUBJID":"PSIVISSIG0002_411","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.91718,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":412,"USUBJID":"PSIVISSIG0002_412","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.92745,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":413,"USUBJID":"PSIVISSIG0002_413","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04791,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":414,"USUBJID":"PSIVISSIG0002_414","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.94182,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":415,"USUBJID":"PSIVISSIG0002_415","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.85626,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":416,"USUBJID":"PSIVISSIG0002_416","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.3922,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":417,"USUBJID":"PSIVISSIG0002_417","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.65024,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":418,"USUBJID":"PSIVISSIG0002_418","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.75359,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":419,"USUBJID":"PSIVISSIG0002_419","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.97399,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":420,"USUBJID":"PSIVISSIG0002_420","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25394,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":421,"USUBJID":"PSIVISSIG0002_421","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.89459,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":422,"USUBJID":"PSIVISSIG0002_422","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49829,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":423,"USUBJID":"PSIVISSIG0002_423","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97741,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":424,"USUBJID":"PSIVISSIG0002_424","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84531,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":425,"USUBJID":"PSIVISSIG0002_425","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.26352,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":426,"USUBJID":"PSIVISSIG0002_426","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51951,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":427,"USUBJID":"PSIVISSIG0002_427","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57426,"CNSR":1,"EVNTDESC":"Second next-line therapy initiated","CNSDTDSC":"Censored at the end date of the next-line therapy","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":428,"USUBJID":"PSIVISSIG0002_428","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.55715,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":429,"USUBJID":"PSIVISSIG0002_429","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51403,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":430,"USUBJID":"PSIVISSIG0002_430","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.18617,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":431,"USUBJID":"PSIVISSIG0002_431","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02875,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":432,"USUBJID":"PSIVISSIG0002_432","AGE":48,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.09582,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":433,"USUBJID":"PSIVISSIG0002_433","AGE":38,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.16632,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":434,"USUBJID":"PSIVISSIG0002_434","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.31896,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":435,"USUBJID":"PSIVISSIG0002_435","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9692,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":436,"USUBJID":"PSIVISSIG0002_436","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.07871,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":437,"USUBJID":"PSIVISSIG0002_437","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57426,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":438,"USUBJID":"PSIVISSIG0002_438","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79124,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":439,"USUBJID":"PSIVISSIG0002_439","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.17317,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":440,"USUBJID":"PSIVISSIG0002_440","AGE":92,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.93498,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":441,"USUBJID":"PSIVISSIG0002_441","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36824,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":442,"USUBJID":"PSIVISSIG0002_442","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.12731,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":443,"USUBJID":"PSIVISSIG0002_443","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66804,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":444,"USUBJID":"PSIVISSIG0002_444","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.41889,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":445,"USUBJID":"PSIVISSIG0002_445","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.09035,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":446,"USUBJID":"PSIVISSIG0002_446","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0178,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":447,"USUBJID":"PSIVISSIG0002_447","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28953,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":448,"USUBJID":"PSIVISSIG0002_448","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72485,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":449,"USUBJID":"PSIVISSIG0002_449","AGE":84,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.38056,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":450,"USUBJID":"PSIVISSIG0002_450","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.55373,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":451,"USUBJID":"PSIVISSIG0002_451","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49829,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":452,"USUBJID":"PSIVISSIG0002_452","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61533,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":453,"USUBJID":"PSIVISSIG0002_453","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.05681,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":454,"USUBJID":"PSIVISSIG0002_454","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.20739,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":455,"USUBJID":"PSIVISSIG0002_455","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.5989,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":456,"USUBJID":"PSIVISSIG0002_456","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.13279,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":457,"USUBJID":"PSIVISSIG0002_457","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.92745,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":458,"USUBJID":"PSIVISSIG0002_458","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.30595,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":459,"USUBJID":"PSIVISSIG0002_459","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82409,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":460,"USUBJID":"PSIVISSIG0002_460","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.13347,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":461,"USUBJID":"PSIVISSIG0002_461","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.04586,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":462,"USUBJID":"PSIVISSIG0002_462","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.59343,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":463,"USUBJID":"PSIVISSIG0002_463","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.18344,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":464,"USUBJID":"PSIVISSIG0002_464","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.14511,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":465,"USUBJID":"PSIVISSIG0002_465","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.53593,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":466,"USUBJID":"PSIVISSIG0002_466","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48392,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":467,"USUBJID":"PSIVISSIG0002_467","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.13415,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":468,"USUBJID":"PSIVISSIG0002_468","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.01643,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":469,"USUBJID":"PSIVISSIG0002_469","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.12047,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":470,"USUBJID":"PSIVISSIG0002_470","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.28063,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":471,"USUBJID":"PSIVISSIG0002_471","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34634,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":472,"USUBJID":"PSIVISSIG0002_472","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63792,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":473,"USUBJID":"PSIVISSIG0002_473","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56331,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":474,"USUBJID":"PSIVISSIG0002_474","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.31691,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":475,"USUBJID":"PSIVISSIG0002_475","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.27515,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":476,"USUBJID":"PSIVISSIG0002_476","AGE":25,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.15469,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":477,"USUBJID":"PSIVISSIG0002_477","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65708,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":478,"USUBJID":"PSIVISSIG0002_478","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.62971,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":479,"USUBJID":"PSIVISSIG0002_479","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11431,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":480,"USUBJID":"PSIVISSIG0002_480","AGE":92,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.95414,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":481,"USUBJID":"PSIVISSIG0002_481","AGE":88,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95551,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":482,"USUBJID":"PSIVISSIG0002_482","AGE":85,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.10404,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":483,"USUBJID":"PSIVISSIG0002_483","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.46817,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":484,"USUBJID":"PSIVISSIG0002_484","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.21355,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":485,"USUBJID":"PSIVISSIG0002_485","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.19713,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":486,"USUBJID":"PSIVISSIG0002_486","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.58316,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":487,"USUBJID":"PSIVISSIG0002_487","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69268,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":488,"USUBJID":"PSIVISSIG0002_488","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.83915,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":489,"USUBJID":"PSIVISSIG0002_489","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49008,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":490,"USUBJID":"PSIVISSIG0002_490","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63244,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":491,"USUBJID":"PSIVISSIG0002_491","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08966,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":492,"USUBJID":"PSIVISSIG0002_492","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.20739,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":493,"USUBJID":"PSIVISSIG0002_493","AGE":88,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93361,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":494,"USUBJID":"PSIVISSIG0002_494","AGE":47,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49281,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":495,"USUBJID":"PSIVISSIG0002_495","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.2204,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":496,"USUBJID":"PSIVISSIG0002_496","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.13279,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":497,"USUBJID":"PSIVISSIG0002_497","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.55236,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":498,"USUBJID":"PSIVISSIG0002_498","AGE":38,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.16906,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":499,"USUBJID":"PSIVISSIG0002_499","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.05955,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":500,"USUBJID":"PSIVISSIG0002_500","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.0486,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":501,"USUBJID":"PSIVISSIG0002_501","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.68583,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":502,"USUBJID":"PSIVISSIG0002_502","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33949,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":503,"USUBJID":"PSIVISSIG0002_503","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.45106,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":504,"USUBJID":"PSIVISSIG0002_504","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.88433,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":505,"USUBJID":"PSIVISSIG0002_505","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79671,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":506,"USUBJID":"PSIVISSIG0002_506","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.38877,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":507,"USUBJID":"PSIVISSIG0002_507","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.93566,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":508,"USUBJID":"PSIVISSIG0002_508","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.15469,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":509,"USUBJID":"PSIVISSIG0002_509","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.90554,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":510,"USUBJID":"PSIVISSIG0002_510","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.58453,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":511,"USUBJID":"PSIVISSIG0002_511","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.75702,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":512,"USUBJID":"PSIVISSIG0002_512","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.88364,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":513,"USUBJID":"PSIVISSIG0002_513","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.71116,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":514,"USUBJID":"PSIVISSIG0002_514","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.22313,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":515,"USUBJID":"PSIVISSIG0002_515","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0835,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":516,"USUBJID":"PSIVISSIG0002_516","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.89322,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":517,"USUBJID":"PSIVISSIG0002_517","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00958,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":518,"USUBJID":"PSIVISSIG0002_518","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.13552,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":519,"USUBJID":"PSIVISSIG0002_519","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69268,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":520,"USUBJID":"PSIVISSIG0002_520","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65161,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":521,"USUBJID":"PSIVISSIG0002_521","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04517,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":522,"USUBJID":"PSIVISSIG0002_522","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26762,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":523,"USUBJID":"PSIVISSIG0002_523","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04107,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":524,"USUBJID":"PSIVISSIG0002_524","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.53457,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":525,"USUBJID":"PSIVISSIG0002_525","AGE":53,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96509,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":526,"USUBJID":"PSIVISSIG0002_526","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69815,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":527,"USUBJID":"PSIVISSIG0002_527","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.95962,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":528,"USUBJID":"PSIVISSIG0002_528","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36824,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":529,"USUBJID":"PSIVISSIG0002_529","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.31417,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":530,"USUBJID":"PSIVISSIG0002_530","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.34428,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":531,"USUBJID":"PSIVISSIG0002_531","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.13415,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":532,"USUBJID":"PSIVISSIG0002_532","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17659,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":533,"USUBJID":"PSIVISSIG0002_533","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.88227,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":534,"USUBJID":"PSIVISSIG0002_534","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.89049,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":535,"USUBJID":"PSIVISSIG0002_535","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.11088,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":536,"USUBJID":"PSIVISSIG0002_536","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85695,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":537,"USUBJID":"PSIVISSIG0002_537","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17385,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":538,"USUBJID":"PSIVISSIG0002_538","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05613,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":539,"USUBJID":"PSIVISSIG0002_539","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26762,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":540,"USUBJID":"PSIVISSIG0002_540","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78576,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":541,"USUBJID":"PSIVISSIG0002_541","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.70363,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":542,"USUBJID":"PSIVISSIG0002_542","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.73648,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":543,"USUBJID":"PSIVISSIG0002_543","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.8768,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":544,"USUBJID":"PSIVISSIG0002_544","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.93771,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":545,"USUBJID":"PSIVISSIG0002_545","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.57769,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":546,"USUBJID":"PSIVISSIG0002_546","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.10815,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":547,"USUBJID":"PSIVISSIG0002_547","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68925,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":548,"USUBJID":"PSIVISSIG0002_548","AGE":68,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94114,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":549,"USUBJID":"PSIVISSIG0002_549","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.86653,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":550,"USUBJID":"PSIVISSIG0002_550","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.59685,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":551,"USUBJID":"PSIVISSIG0002_551","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20671,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":552,"USUBJID":"PSIVISSIG0002_552","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.58795,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":553,"USUBJID":"PSIVISSIG0002_553","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65982,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":554,"USUBJID":"PSIVISSIG0002_554","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.3833,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":555,"USUBJID":"PSIVISSIG0002_555","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.91923,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":556,"USUBJID":"PSIVISSIG0002_556","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.20329,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":557,"USUBJID":"PSIVISSIG0002_557","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.1499,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":558,"USUBJID":"PSIVISSIG0002_558","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28131,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":559,"USUBJID":"PSIVISSIG0002_559","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.55784,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":560,"USUBJID":"PSIVISSIG0002_560","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.52635,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":561,"USUBJID":"PSIVISSIG0002_561","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19028,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":562,"USUBJID":"PSIVISSIG0002_562","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.86448,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":563,"USUBJID":"PSIVISSIG0002_563","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9473,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":564,"USUBJID":"PSIVISSIG0002_564","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.94182,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":565,"USUBJID":"PSIVISSIG0002_565","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.705,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":566,"USUBJID":"PSIVISSIG0002_566","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.58522,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":567,"USUBJID":"PSIVISSIG0002_567","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08145,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":568,"USUBJID":"PSIVISSIG0002_568","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.69131,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":569,"USUBJID":"PSIVISSIG0002_569","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11704,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":570,"USUBJID":"PSIVISSIG0002_570","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.84394,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":571,"USUBJID":"PSIVISSIG0002_571","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67625,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":572,"USUBJID":"PSIVISSIG0002_572","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.58179,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":573,"USUBJID":"PSIVISSIG0002_573","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81588,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":574,"USUBJID":"PSIVISSIG0002_574","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.15811,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":575,"USUBJID":"PSIVISSIG0002_575","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79945,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":576,"USUBJID":"PSIVISSIG0002_576","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.59754,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":577,"USUBJID":"PSIVISSIG0002_577","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49966,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":578,"USUBJID":"PSIVISSIG0002_578","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.91102,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":579,"USUBJID":"PSIVISSIG0002_579","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.8501,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":580,"USUBJID":"PSIVISSIG0002_580","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85695,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":581,"USUBJID":"PSIVISSIG0002_581","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.75291,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":582,"USUBJID":"PSIVISSIG0002_582","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.63313,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":583,"USUBJID":"PSIVISSIG0002_583","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.04107,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":584,"USUBJID":"PSIVISSIG0002_584","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17659,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":585,"USUBJID":"PSIVISSIG0002_585","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93634,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":586,"USUBJID":"PSIVISSIG0002_586","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.16838,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":587,"USUBJID":"PSIVISSIG0002_587","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.98973,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":588,"USUBJID":"PSIVISSIG0002_588","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.77481,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":589,"USUBJID":"PSIVISSIG0002_589","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.84394,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":590,"USUBJID":"PSIVISSIG0002_590","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47502,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":591,"USUBJID":"PSIVISSIG0002_591","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.24778,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":592,"USUBJID":"PSIVISSIG0002_592","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.23888,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":593,"USUBJID":"PSIVISSIG0002_593","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34908,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":594,"USUBJID":"PSIVISSIG0002_594","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82957,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":595,"USUBJID":"PSIVISSIG0002_595","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.60027,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":596,"USUBJID":"PSIVISSIG0002_596","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93361,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":597,"USUBJID":"PSIVISSIG0002_597","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6345,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":598,"USUBJID":"PSIVISSIG0002_598","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.19644,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":599,"USUBJID":"PSIVISSIG0002_599","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42094,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":600,"USUBJID":"PSIVISSIG0002_600","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7447,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":601,"USUBJID":"PSIVISSIG0002_601","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04517,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":602,"USUBJID":"PSIVISSIG0002_602","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72279,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":603,"USUBJID":"PSIVISSIG0002_603","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.80698,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":604,"USUBJID":"PSIVISSIG0002_604","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.8193,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":605,"USUBJID":"PSIVISSIG0002_605","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.83778,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":606,"USUBJID":"PSIVISSIG0002_606","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64066,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":607,"USUBJID":"PSIVISSIG0002_607","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93087,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":608,"USUBJID":"PSIVISSIG0002_608","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.62218,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":609,"USUBJID":"PSIVISSIG0002_609","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.2334,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":610,"USUBJID":"PSIVISSIG0002_610","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.23682,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":611,"USUBJID":"PSIVISSIG0002_611","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05613,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":612,"USUBJID":"PSIVISSIG0002_612","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93361,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":613,"USUBJID":"PSIVISSIG0002_613","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08145,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":614,"USUBJID":"PSIVISSIG0002_614","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72485,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":615,"USUBJID":"PSIVISSIG0002_615","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.27036,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":616,"USUBJID":"PSIVISSIG0002_616","AGE":82,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42368,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":617,"USUBJID":"PSIVISSIG0002_617","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.62218,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":618,"USUBJID":"PSIVISSIG0002_618","AGE":47,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52019,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":619,"USUBJID":"PSIVISSIG0002_619","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.09514,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":620,"USUBJID":"PSIVISSIG0002_620","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.53867,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":621,"USUBJID":"PSIVISSIG0002_621","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.53388,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":622,"USUBJID":"PSIVISSIG0002_622","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36277,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":623,"USUBJID":"PSIVISSIG0002_623","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.16427,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":624,"USUBJID":"PSIVISSIG0002_624","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33949,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":625,"USUBJID":"PSIVISSIG0002_625","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.07598,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":626,"USUBJID":"PSIVISSIG0002_626","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.88159,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":627,"USUBJID":"PSIVISSIG0002_627","AGE":44,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.53114,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":628,"USUBJID":"PSIVISSIG0002_628","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.86448,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":629,"USUBJID":"PSIVISSIG0002_629","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.82546,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":630,"USUBJID":"PSIVISSIG0002_630","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7091,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":631,"USUBJID":"PSIVISSIG0002_631","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08145,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":632,"USUBJID":"PSIVISSIG0002_632","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21287,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":633,"USUBJID":"PSIVISSIG0002_633","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.62081,"CNSR":1,"EVNTDESC":"Second next-line therapy initiated","CNSDTDSC":"Censored at the end date of the next-line therapy","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":634,"USUBJID":"PSIVISSIG0002_634","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72211,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":635,"USUBJID":"PSIVISSIG0002_635","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.19439,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":636,"USUBJID":"PSIVISSIG0002_636","AGE":82,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7666,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":637,"USUBJID":"PSIVISSIG0002_637","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.65914,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":638,"USUBJID":"PSIVISSIG0002_638","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.01506,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":639,"USUBJID":"PSIVISSIG0002_639","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.13621,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":640,"USUBJID":"PSIVISSIG0002_640","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78576,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":641,"USUBJID":"PSIVISSIG0002_641","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.15469,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":642,"USUBJID":"PSIVISSIG0002_642","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47502,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":643,"USUBJID":"PSIVISSIG0002_643","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.1718,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":644,"USUBJID":"PSIVISSIG0002_644","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.69747,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":645,"USUBJID":"PSIVISSIG0002_645","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.35797,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":646,"USUBJID":"PSIVISSIG0002_646","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04107,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":647,"USUBJID":"PSIVISSIG0002_647","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21561,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":648,"USUBJID":"PSIVISSIG0002_648","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12799,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":649,"USUBJID":"PSIVISSIG0002_649","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.295,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":650,"USUBJID":"PSIVISSIG0002_650","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68172,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":651,"USUBJID":"PSIVISSIG0002_651","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68652,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":652,"USUBJID":"PSIVISSIG0002_652","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.80151,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":653,"USUBJID":"PSIVISSIG0002_653","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.58248,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":654,"USUBJID":"PSIVISSIG0002_654","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.59959,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":655,"USUBJID":"PSIVISSIG0002_655","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24572,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":656,"USUBJID":"PSIVISSIG0002_656","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04244,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":657,"USUBJID":"PSIVISSIG0002_657","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.68789,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":658,"USUBJID":"PSIVISSIG0002_658","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.94867,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":659,"USUBJID":"PSIVISSIG0002_659","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.50376,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":660,"USUBJID":"PSIVISSIG0002_660","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.67488,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":661,"USUBJID":"PSIVISSIG0002_661","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.32307,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":662,"USUBJID":"PSIVISSIG0002_662","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.74401,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":663,"USUBJID":"PSIVISSIG0002_663","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.86585,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":664,"USUBJID":"PSIVISSIG0002_664","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.5243,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":665,"USUBJID":"PSIVISSIG0002_665","AGE":44,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.13073,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":666,"USUBJID":"PSIVISSIG0002_666","AGE":80,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63518,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":667,"USUBJID":"PSIVISSIG0002_667","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.97399,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":668,"USUBJID":"PSIVISSIG0002_668","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.34702,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":669,"USUBJID":"PSIVISSIG0002_669","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.03696,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":670,"USUBJID":"PSIVISSIG0002_670","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.41547,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":671,"USUBJID":"PSIVISSIG0002_671","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.32033,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":672,"USUBJID":"PSIVISSIG0002_672","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.86037,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":673,"USUBJID":"PSIVISSIG0002_673","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.48871,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":674,"USUBJID":"PSIVISSIG0002_674","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05065,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":675,"USUBJID":"PSIVISSIG0002_675","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4538,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":676,"USUBJID":"PSIVISSIG0002_676","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.60096,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":677,"USUBJID":"PSIVISSIG0002_677","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23203,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":678,"USUBJID":"PSIVISSIG0002_678","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.84736,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":679,"USUBJID":"PSIVISSIG0002_679","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.85284,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":680,"USUBJID":"PSIVISSIG0002_680","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.69952,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":681,"USUBJID":"PSIVISSIG0002_681","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65435,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":682,"USUBJID":"PSIVISSIG0002_682","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.20602,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":683,"USUBJID":"PSIVISSIG0002_683","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.83436,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":684,"USUBJID":"PSIVISSIG0002_684","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57974,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":685,"USUBJID":"PSIVISSIG0002_685","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68172,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":686,"USUBJID":"PSIVISSIG0002_686","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.76591,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":687,"USUBJID":"PSIVISSIG0002_687","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.73648,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":688,"USUBJID":"PSIVISSIG0002_688","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79671,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":689,"USUBJID":"PSIVISSIG0002_689","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65161,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":690,"USUBJID":"PSIVISSIG0002_690","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67899,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":691,"USUBJID":"PSIVISSIG0002_691","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.27858,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":692,"USUBJID":"PSIVISSIG0002_692","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.4449,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":693,"USUBJID":"PSIVISSIG0002_693","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6783,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":694,"USUBJID":"PSIVISSIG0002_694","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.87543,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":695,"USUBJID":"PSIVISSIG0002_695","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.69062,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":696,"USUBJID":"PSIVISSIG0002_696","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96235,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":697,"USUBJID":"PSIVISSIG0002_697","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21013,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":698,"USUBJID":"PSIVISSIG0002_698","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7091,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":699,"USUBJID":"PSIVISSIG0002_699","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78576,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":700,"USUBJID":"PSIVISSIG0002_700","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08966,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":701,"USUBJID":"PSIVISSIG0002_701","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23477,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":702,"USUBJID":"PSIVISSIG0002_702","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.17248,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":703,"USUBJID":"PSIVISSIG0002_703","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.20602,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":704,"USUBJID":"PSIVISSIG0002_704","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.86448,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":705,"USUBJID":"PSIVISSIG0002_705","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.75154,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":706,"USUBJID":"PSIVISSIG0002_706","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87337,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":707,"USUBJID":"PSIVISSIG0002_707","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.48049,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":708,"USUBJID":"PSIVISSIG0002_708","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35318,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":709,"USUBJID":"PSIVISSIG0002_709","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.87817,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":710,"USUBJID":"PSIVISSIG0002_710","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.89938,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":711,"USUBJID":"PSIVISSIG0002_711","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.87817,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":712,"USUBJID":"PSIVISSIG0002_712","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.98152,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":713,"USUBJID":"PSIVISSIG0002_713","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.52498,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":714,"USUBJID":"PSIVISSIG0002_714","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52019,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":715,"USUBJID":"PSIVISSIG0002_715","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.47296,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":716,"USUBJID":"PSIVISSIG0002_716","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33128,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":717,"USUBJID":"PSIVISSIG0002_717","AGE":82,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80219,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":718,"USUBJID":"PSIVISSIG0002_718","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05065,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":719,"USUBJID":"PSIVISSIG0002_719","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.60712,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":720,"USUBJID":"PSIVISSIG0002_720","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.16359,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":721,"USUBJID":"PSIVISSIG0002_721","AGE":37,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.64545,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":722,"USUBJID":"PSIVISSIG0002_722","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.97399,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":723,"USUBJID":"PSIVISSIG0002_723","AGE":38,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.1499,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":724,"USUBJID":"PSIVISSIG0002_724","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10883,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":725,"USUBJID":"PSIVISSIG0002_725","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64887,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":726,"USUBJID":"PSIVISSIG0002_726","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.75565,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":727,"USUBJID":"PSIVISSIG0002_727","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.67009,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":728,"USUBJID":"PSIVISSIG0002_728","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.58453,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":729,"USUBJID":"PSIVISSIG0002_729","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.43463,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":730,"USUBJID":"PSIVISSIG0002_730","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.88433,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":731,"USUBJID":"PSIVISSIG0002_731","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.59138,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":732,"USUBJID":"PSIVISSIG0002_732","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.27105,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":733,"USUBJID":"PSIVISSIG0002_733","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.77892,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":734,"USUBJID":"PSIVISSIG0002_734","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.1013,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":735,"USUBJID":"PSIVISSIG0002_735","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.21766,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":736,"USUBJID":"PSIVISSIG0002_736","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.03696,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":737,"USUBJID":"PSIVISSIG0002_737","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.03833,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":738,"USUBJID":"PSIVISSIG0002_738","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.19097,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":739,"USUBJID":"PSIVISSIG0002_739","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84805,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":740,"USUBJID":"PSIVISSIG0002_740","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.59548,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":741,"USUBJID":"PSIVISSIG0002_741","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.58932,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":742,"USUBJID":"PSIVISSIG0002_742","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.32307,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":743,"USUBJID":"PSIVISSIG0002_743","AGE":43,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.50376,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":744,"USUBJID":"PSIVISSIG0002_744","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.38261,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":745,"USUBJID":"PSIVISSIG0002_745","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.97399,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":746,"USUBJID":"PSIVISSIG0002_746","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72485,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":747,"USUBJID":"PSIVISSIG0002_747","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.18344,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":748,"USUBJID":"PSIVISSIG0002_748","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.00479,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":749,"USUBJID":"PSIVISSIG0002_749","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11431,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":750,"USUBJID":"PSIVISSIG0002_750","AGE":39,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.09788,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":751,"USUBJID":"PSIVISSIG0002_751","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.21355,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":752,"USUBJID":"PSIVISSIG0002_752","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.63723,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":753,"USUBJID":"PSIVISSIG0002_753","AGE":40,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.4846,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":754,"USUBJID":"PSIVISSIG0002_754","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.30459,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":755,"USUBJID":"PSIVISSIG0002_755","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.52225,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":756,"USUBJID":"PSIVISSIG0002_756","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51951,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":757,"USUBJID":"PSIVISSIG0002_757","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.70637,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":758,"USUBJID":"PSIVISSIG0002_758","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.45996,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":759,"USUBJID":"PSIVISSIG0002_759","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.32033,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":760,"USUBJID":"PSIVISSIG0002_760","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.22108,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":761,"USUBJID":"PSIVISSIG0002_761","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.03285,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":762,"USUBJID":"PSIVISSIG0002_762","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.92745,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":763,"USUBJID":"PSIVISSIG0002_763","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.16427,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":764,"USUBJID":"PSIVISSIG0002_764","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.83231,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":765,"USUBJID":"PSIVISSIG0002_765","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.41821,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":766,"USUBJID":"PSIVISSIG0002_766","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.91376,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":767,"USUBJID":"PSIVISSIG0002_767","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.39699,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":768,"USUBJID":"PSIVISSIG0002_768","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.94182,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":769,"USUBJID":"PSIVISSIG0002_769","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.61875,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":770,"USUBJID":"PSIVISSIG0002_770","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.83847,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":771,"USUBJID":"PSIVISSIG0002_771","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.41547,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":772,"USUBJID":"PSIVISSIG0002_772","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.42026,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":773,"USUBJID":"PSIVISSIG0002_773","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.31964,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":774,"USUBJID":"PSIVISSIG0002_774","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.3217,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":775,"USUBJID":"PSIVISSIG0002_775","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56879,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":776,"USUBJID":"PSIVISSIG0002_776","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.70226,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":777,"USUBJID":"PSIVISSIG0002_777","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0835,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":778,"USUBJID":"PSIVISSIG0002_778","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.85147,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":779,"USUBJID":"PSIVISSIG0002_779","AGE":80,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.61602,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":780,"USUBJID":"PSIVISSIG0002_780","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65708,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":781,"USUBJID":"PSIVISSIG0002_781","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.71869,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":782,"USUBJID":"PSIVISSIG0002_782","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81314,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":783,"USUBJID":"PSIVISSIG0002_783","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.98015,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":784,"USUBJID":"PSIVISSIG0002_784","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85421,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":785,"USUBJID":"PSIVISSIG0002_785","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.70363,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":786,"USUBJID":"PSIVISSIG0002_786","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.01643,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":787,"USUBJID":"PSIVISSIG0002_787","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.90212,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":788,"USUBJID":"PSIVISSIG0002_788","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.77687,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":789,"USUBJID":"PSIVISSIG0002_789","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7885,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":790,"USUBJID":"PSIVISSIG0002_790","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.69952,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":791,"USUBJID":"PSIVISSIG0002_791","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.60027,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":792,"USUBJID":"PSIVISSIG0002_792","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.57632,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":793,"USUBJID":"PSIVISSIG0002_793","AGE":85,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.12047,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":794,"USUBJID":"PSIVISSIG0002_794","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.50513,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":795,"USUBJID":"PSIVISSIG0002_795","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.18549,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":796,"USUBJID":"PSIVISSIG0002_796","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80493,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":797,"USUBJID":"PSIVISSIG0002_797","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94114,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":798,"USUBJID":"PSIVISSIG0002_798","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.4627,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":799,"USUBJID":"PSIVISSIG0002_799","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.38809,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":800,"USUBJID":"PSIVISSIG0002_800","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.84326,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":801,"USUBJID":"PSIVISSIG0002_801","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.59274,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":802,"USUBJID":"PSIVISSIG0002_802","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81862,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":803,"USUBJID":"PSIVISSIG0002_803","AGE":37,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.65092,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":804,"USUBJID":"PSIVISSIG0002_804","AGE":35,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.80151,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":805,"USUBJID":"PSIVISSIG0002_805","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.1191,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":806,"USUBJID":"PSIVISSIG0002_806","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49144,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":807,"USUBJID":"PSIVISSIG0002_807","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.24093,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":808,"USUBJID":"PSIVISSIG0002_808","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23477,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":809,"USUBJID":"PSIVISSIG0002_809","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.34292,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":810,"USUBJID":"PSIVISSIG0002_810","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69541,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":811,"USUBJID":"PSIVISSIG0002_811","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.98084,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":812,"USUBJID":"PSIVISSIG0002_812","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51129,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":813,"USUBJID":"PSIVISSIG0002_813","AGE":80,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.74743,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":814,"USUBJID":"PSIVISSIG0002_814","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.02122,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":815,"USUBJID":"PSIVISSIG0002_815","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.22998,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":816,"USUBJID":"PSIVISSIG0002_816","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.51882,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":817,"USUBJID":"PSIVISSIG0002_817","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.6653,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":818,"USUBJID":"PSIVISSIG0002_818","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.32717,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":819,"USUBJID":"PSIVISSIG0002_819","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11431,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":820,"USUBJID":"PSIVISSIG0002_820","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65435,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":821,"USUBJID":"PSIVISSIG0002_821","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.26626,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":822,"USUBJID":"PSIVISSIG0002_822","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9911,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":823,"USUBJID":"PSIVISSIG0002_823","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40452,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":824,"USUBJID":"PSIVISSIG0002_824","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.97947,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":825,"USUBJID":"PSIVISSIG0002_825","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69541,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":826,"USUBJID":"PSIVISSIG0002_826","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04244,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":827,"USUBJID":"PSIVISSIG0002_827","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.88296,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":828,"USUBJID":"PSIVISSIG0002_828","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85147,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":829,"USUBJID":"PSIVISSIG0002_829","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72758,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":830,"USUBJID":"PSIVISSIG0002_830","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52293,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":831,"USUBJID":"PSIVISSIG0002_831","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81999,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":832,"USUBJID":"PSIVISSIG0002_832","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.92266,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":833,"USUBJID":"PSIVISSIG0002_833","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7447,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":834,"USUBJID":"PSIVISSIG0002_834","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.8809,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":835,"USUBJID":"PSIVISSIG0002_835","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33128,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":836,"USUBJID":"PSIVISSIG0002_836","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.69131,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":837,"USUBJID":"PSIVISSIG0002_837","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.0705,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":838,"USUBJID":"PSIVISSIG0002_838","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.92471,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":839,"USUBJID":"PSIVISSIG0002_839","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26215,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":840,"USUBJID":"PSIVISSIG0002_840","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4757,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":841,"USUBJID":"PSIVISSIG0002_841","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.5332,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":842,"USUBJID":"PSIVISSIG0002_842","AGE":53,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.36345,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":843,"USUBJID":"PSIVISSIG0002_843","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23477,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":844,"USUBJID":"PSIVISSIG0002_844","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19849,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":845,"USUBJID":"PSIVISSIG0002_845","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23203,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":846,"USUBJID":"PSIVISSIG0002_846","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.65572,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":847,"USUBJID":"PSIVISSIG0002_847","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.53799,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":848,"USUBJID":"PSIVISSIG0002_848","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.43463,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":849,"USUBJID":"PSIVISSIG0002_849","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00411,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":850,"USUBJID":"PSIVISSIG0002_850","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33812,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":851,"USUBJID":"PSIVISSIG0002_851","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36824,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":852,"USUBJID":"PSIVISSIG0002_852","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.24162,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":853,"USUBJID":"PSIVISSIG0002_853","AGE":38,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63244,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":854,"USUBJID":"PSIVISSIG0002_854","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25667,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":855,"USUBJID":"PSIVISSIG0002_855","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62423,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":856,"USUBJID":"PSIVISSIG0002_856","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.76454,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":857,"USUBJID":"PSIVISSIG0002_857","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65435,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":858,"USUBJID":"PSIVISSIG0002_858","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62149,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":859,"USUBJID":"PSIVISSIG0002_859","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.01985,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":860,"USUBJID":"PSIVISSIG0002_860","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.05202,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":861,"USUBJID":"PSIVISSIG0002_861","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.09377,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":862,"USUBJID":"PSIVISSIG0002_862","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40999,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":863,"USUBJID":"PSIVISSIG0002_863","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72553,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":864,"USUBJID":"PSIVISSIG0002_864","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.76797,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":865,"USUBJID":"PSIVISSIG0002_865","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.74333,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":866,"USUBJID":"PSIVISSIG0002_866","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97741,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":867,"USUBJID":"PSIVISSIG0002_867","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.62628,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":868,"USUBJID":"PSIVISSIG0002_868","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.15195,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":869,"USUBJID":"PSIVISSIG0002_869","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05886,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":870,"USUBJID":"PSIVISSIG0002_870","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68104,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":871,"USUBJID":"PSIVISSIG0002_871","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.9911,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":872,"USUBJID":"PSIVISSIG0002_872","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54689,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":873,"USUBJID":"PSIVISSIG0002_873","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.26146,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":874,"USUBJID":"PSIVISSIG0002_874","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.79329,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":875,"USUBJID":"PSIVISSIG0002_875","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.54209,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":876,"USUBJID":"PSIVISSIG0002_876","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.64271,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":877,"USUBJID":"PSIVISSIG0002_877","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.55099,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":878,"USUBJID":"PSIVISSIG0002_878","AGE":92,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.92129,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":879,"USUBJID":"PSIVISSIG0002_879","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81588,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":880,"USUBJID":"PSIVISSIG0002_880","AGE":53,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51472,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":881,"USUBJID":"PSIVISSIG0002_881","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72279,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":882,"USUBJID":"PSIVISSIG0002_882","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.52909,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":883,"USUBJID":"PSIVISSIG0002_883","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95003,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":884,"USUBJID":"PSIVISSIG0002_884","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67899,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":885,"USUBJID":"PSIVISSIG0002_885","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.32238,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":886,"USUBJID":"PSIVISSIG0002_886","AGE":83,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.8809,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":887,"USUBJID":"PSIVISSIG0002_887","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.84668,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":888,"USUBJID":"PSIVISSIG0002_888","AGE":78,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.35181,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":889,"USUBJID":"PSIVISSIG0002_889","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28679,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":890,"USUBJID":"PSIVISSIG0002_890","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.12868,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":891,"USUBJID":"PSIVISSIG0002_891","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.67077,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":892,"USUBJID":"PSIVISSIG0002_892","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.17728,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":893,"USUBJID":"PSIVISSIG0002_893","AGE":82,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4319,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":894,"USUBJID":"PSIVISSIG0002_894","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.05749,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":895,"USUBJID":"PSIVISSIG0002_895","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62971,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":896,"USUBJID":"PSIVISSIG0002_896","AGE":53,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.46817,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":897,"USUBJID":"PSIVISSIG0002_897","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.09103,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":898,"USUBJID":"PSIVISSIG0002_898","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.32512,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":899,"USUBJID":"PSIVISSIG0002_899","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.27173,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":900,"USUBJID":"PSIVISSIG0002_900","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.78439,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":901,"USUBJID":"PSIVISSIG0002_901","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72485,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":902,"USUBJID":"PSIVISSIG0002_902","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.20465,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":903,"USUBJID":"PSIVISSIG0002_903","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9911,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":904,"USUBJID":"PSIVISSIG0002_904","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.74127,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":905,"USUBJID":"PSIVISSIG0002_905","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.18754,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":906,"USUBJID":"PSIVISSIG0002_906","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.68994,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":907,"USUBJID":"PSIVISSIG0002_907","AGE":53,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.94593,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":908,"USUBJID":"PSIVISSIG0002_908","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.57769,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":909,"USUBJID":"PSIVISSIG0002_909","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.56742,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":910,"USUBJID":"PSIVISSIG0002_910","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.846,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":911,"USUBJID":"PSIVISSIG0002_911","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04244,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":912,"USUBJID":"PSIVISSIG0002_912","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.50582,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":913,"USUBJID":"PSIVISSIG0002_913","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81314,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":914,"USUBJID":"PSIVISSIG0002_914","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.39083,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":915,"USUBJID":"PSIVISSIG0002_915","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.73648,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":916,"USUBJID":"PSIVISSIG0002_916","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.80356,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":917,"USUBJID":"PSIVISSIG0002_917","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.69747,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":918,"USUBJID":"PSIVISSIG0002_918","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.80698,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":919,"USUBJID":"PSIVISSIG0002_919","AGE":47,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51472,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":920,"USUBJID":"PSIVISSIG0002_920","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96235,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":921,"USUBJID":"PSIVISSIG0002_921","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54689,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":922,"USUBJID":"PSIVISSIG0002_922","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.35592,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":923,"USUBJID":"PSIVISSIG0002_923","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.92676,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":924,"USUBJID":"PSIVISSIG0002_924","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.98015,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":925,"USUBJID":"PSIVISSIG0002_925","AGE":84,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.38877,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":926,"USUBJID":"PSIVISSIG0002_926","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.40246,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":927,"USUBJID":"PSIVISSIG0002_927","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.41068,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":928,"USUBJID":"PSIVISSIG0002_928","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.30595,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":929,"USUBJID":"PSIVISSIG0002_929","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.2909,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":930,"USUBJID":"PSIVISSIG0002_930","AGE":48,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.42984,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":931,"USUBJID":"PSIVISSIG0002_931","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.64271,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":932,"USUBJID":"PSIVISSIG0002_932","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.5729,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":933,"USUBJID":"PSIVISSIG0002_933","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.50924,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":934,"USUBJID":"PSIVISSIG0002_934","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.60575,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":935,"USUBJID":"PSIVISSIG0002_935","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97604,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":936,"USUBJID":"PSIVISSIG0002_936","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.26968,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":937,"USUBJID":"PSIVISSIG0002_937","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.88706,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":938,"USUBJID":"PSIVISSIG0002_938","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79945,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":939,"USUBJID":"PSIVISSIG0002_939","AGE":77,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25394,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":940,"USUBJID":"PSIVISSIG0002_940","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02053,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":941,"USUBJID":"PSIVISSIG0002_941","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97741,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":942,"USUBJID":"PSIVISSIG0002_942","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.85216,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":943,"USUBJID":"PSIVISSIG0002_943","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.0883,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":944,"USUBJID":"PSIVISSIG0002_944","AGE":68,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.98494,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":945,"USUBJID":"PSIVISSIG0002_945","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36277,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":946,"USUBJID":"PSIVISSIG0002_946","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68994,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":947,"USUBJID":"PSIVISSIG0002_947","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08966,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":948,"USUBJID":"PSIVISSIG0002_948","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.60507,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":949,"USUBJID":"PSIVISSIG0002_949","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.1499,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":950,"USUBJID":"PSIVISSIG0002_950","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0835,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":951,"USUBJID":"PSIVISSIG0002_951","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67625,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":952,"USUBJID":"PSIVISSIG0002_952","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65435,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":953,"USUBJID":"PSIVISSIG0002_953","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69541,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":954,"USUBJID":"PSIVISSIG0002_954","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.81793,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":955,"USUBJID":"PSIVISSIG0002_955","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.76591,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":956,"USUBJID":"PSIVISSIG0002_956","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.06502,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":957,"USUBJID":"PSIVISSIG0002_957","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.54483,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":958,"USUBJID":"PSIVISSIG0002_958","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.53046,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":959,"USUBJID":"PSIVISSIG0002_959","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.78987,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":960,"USUBJID":"PSIVISSIG0002_960","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.07324,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":961,"USUBJID":"PSIVISSIG0002_961","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.32444,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":962,"USUBJID":"PSIVISSIG0002_962","AGE":82,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54141,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":963,"USUBJID":"PSIVISSIG0002_963","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.48323,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":964,"USUBJID":"PSIVISSIG0002_964","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.78508,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":965,"USUBJID":"PSIVISSIG0002_965","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94114,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":966,"USUBJID":"PSIVISSIG0002_966","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.22245,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":967,"USUBJID":"PSIVISSIG0002_967","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72005,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":968,"USUBJID":"PSIVISSIG0002_968","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97604,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":969,"USUBJID":"PSIVISSIG0002_969","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.88569,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":970,"USUBJID":"PSIVISSIG0002_970","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.79261,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":971,"USUBJID":"PSIVISSIG0002_971","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.7358,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":972,"USUBJID":"PSIVISSIG0002_972","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04791,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":973,"USUBJID":"PSIVISSIG0002_973","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81999,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":974,"USUBJID":"PSIVISSIG0002_974","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.22108,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":975,"USUBJID":"PSIVISSIG0002_975","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.30116,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":976,"USUBJID":"PSIVISSIG0002_976","AGE":89,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.44832,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":977,"USUBJID":"PSIVISSIG0002_977","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.22587,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":978,"USUBJID":"PSIVISSIG0002_978","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70021,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":979,"USUBJID":"PSIVISSIG0002_979","AGE":32,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63792,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":980,"USUBJID":"PSIVISSIG0002_980","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94387,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":981,"USUBJID":"PSIVISSIG0002_981","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.1232,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":982,"USUBJID":"PSIVISSIG0002_982","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.31348,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":983,"USUBJID":"PSIVISSIG0002_983","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.38193,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":984,"USUBJID":"PSIVISSIG0002_984","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52841,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":985,"USUBJID":"PSIVISSIG0002_985","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.59959,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":986,"USUBJID":"PSIVISSIG0002_986","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78029,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":987,"USUBJID":"PSIVISSIG0002_987","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.76112,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":988,"USUBJID":"PSIVISSIG0002_988","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.63723,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":989,"USUBJID":"PSIVISSIG0002_989","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.83231,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":990,"USUBJID":"PSIVISSIG0002_990","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.93224,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":991,"USUBJID":"PSIVISSIG0002_991","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.01506,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":992,"USUBJID":"PSIVISSIG0002_992","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28131,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":993,"USUBJID":"PSIVISSIG0002_993","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.17864,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":994,"USUBJID":"PSIVISSIG0002_994","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.41342,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":995,"USUBJID":"PSIVISSIG0002_995","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.22587,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":996,"USUBJID":"PSIVISSIG0002_996","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.75017,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":997,"USUBJID":"PSIVISSIG0002_997","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.42505,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":998,"USUBJID":"PSIVISSIG0002_998","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.31075,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":999,"USUBJID":"PSIVISSIG0002_999","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.01643,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1000,"USUBJID":"PSIVISSIG0002_1000","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.1191,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1001,"USUBJID":"PSIVISSIG0002_1001","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64066,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1002,"USUBJID":"PSIVISSIG0002_1002","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.76591,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1003,"USUBJID":"PSIVISSIG0002_1003","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.295,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1004,"USUBJID":"PSIVISSIG0002_1004","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.46543,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1005,"USUBJID":"PSIVISSIG0002_1005","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.65845,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1006,"USUBJID":"PSIVISSIG0002_1006","AGE":40,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.47091,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1007,"USUBJID":"PSIVISSIG0002_1007","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.55647,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1008,"USUBJID":"PSIVISSIG0002_1008","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.23614,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1009,"USUBJID":"PSIVISSIG0002_1009","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28405,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1010,"USUBJID":"PSIVISSIG0002_1010","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.8063,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1011,"USUBJID":"PSIVISSIG0002_1011","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81588,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1012,"USUBJID":"PSIVISSIG0002_1012","AGE":89,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.47844,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1013,"USUBJID":"PSIVISSIG0002_1013","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.96099,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1014,"USUBJID":"PSIVISSIG0002_1014","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12252,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1015,"USUBJID":"PSIVISSIG0002_1015","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.58248,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1016,"USUBJID":"PSIVISSIG0002_1016","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.66667,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1017,"USUBJID":"PSIVISSIG0002_1017","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.11773,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1018,"USUBJID":"PSIVISSIG0002_1018","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.92676,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1019,"USUBJID":"PSIVISSIG0002_1019","AGE":43,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.48186,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1020,"USUBJID":"PSIVISSIG0002_1020","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.31759,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1021,"USUBJID":"PSIVISSIG0002_1021","AGE":82,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.52772,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1022,"USUBJID":"PSIVISSIG0002_1022","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.93429,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1023,"USUBJID":"PSIVISSIG0002_1023","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68446,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1024,"USUBJID":"PSIVISSIG0002_1024","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28131,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1025,"USUBJID":"PSIVISSIG0002_1025","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.11978,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1026,"USUBJID":"PSIVISSIG0002_1026","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.06571,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1027,"USUBJID":"PSIVISSIG0002_1027","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97878,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1028,"USUBJID":"PSIVISSIG0002_1028","AGE":78,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.71937,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1029,"USUBJID":"PSIVISSIG0002_1029","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34634,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1030,"USUBJID":"PSIVISSIG0002_1030","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26215,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1031,"USUBJID":"PSIVISSIG0002_1031","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.76797,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1032,"USUBJID":"PSIVISSIG0002_1032","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.97399,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1033,"USUBJID":"PSIVISSIG0002_1033","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.94867,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1034,"USUBJID":"PSIVISSIG0002_1034","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.15332,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1035,"USUBJID":"PSIVISSIG0002_1035","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.00821,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1036,"USUBJID":"PSIVISSIG0002_1036","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04517,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1037,"USUBJID":"PSIVISSIG0002_1037","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.48186,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1038,"USUBJID":"PSIVISSIG0002_1038","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.18617,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1039,"USUBJID":"PSIVISSIG0002_1039","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.07598,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1040,"USUBJID":"PSIVISSIG0002_1040","AGE":83,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12526,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1041,"USUBJID":"PSIVISSIG0002_1041","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.68857,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1042,"USUBJID":"PSIVISSIG0002_1042","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6564,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1043,"USUBJID":"PSIVISSIG0002_1043","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.88775,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1044,"USUBJID":"PSIVISSIG0002_1044","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4757,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1045,"USUBJID":"PSIVISSIG0002_1045","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.1807,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1046,"USUBJID":"PSIVISSIG0002_1046","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.90828,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1047,"USUBJID":"PSIVISSIG0002_1047","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6345,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1048,"USUBJID":"PSIVISSIG0002_1048","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.46407,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1049,"USUBJID":"PSIVISSIG0002_1049","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95003,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1050,"USUBJID":"PSIVISSIG0002_1050","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08693,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1051,"USUBJID":"PSIVISSIG0002_1051","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.44764,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1052,"USUBJID":"PSIVISSIG0002_1052","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.10267,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1053,"USUBJID":"PSIVISSIG0002_1053","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.18754,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1054,"USUBJID":"PSIVISSIG0002_1054","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72485,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1055,"USUBJID":"PSIVISSIG0002_1055","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12526,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1056,"USUBJID":"PSIVISSIG0002_1056","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25667,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1057,"USUBJID":"PSIVISSIG0002_1057","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.17796,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1058,"USUBJID":"PSIVISSIG0002_1058","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.16222,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1059,"USUBJID":"PSIVISSIG0002_1059","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.44353,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1060,"USUBJID":"PSIVISSIG0002_1060","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81862,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1061,"USUBJID":"PSIVISSIG0002_1061","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67077,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1062,"USUBJID":"PSIVISSIG0002_1062","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.24162,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1063,"USUBJID":"PSIVISSIG0002_1063","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.49213,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1064,"USUBJID":"PSIVISSIG0002_1064","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.6961,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1065,"USUBJID":"PSIVISSIG0002_1065","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0178,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1066,"USUBJID":"PSIVISSIG0002_1066","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66804,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1067,"USUBJID":"PSIVISSIG0002_1067","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.78097,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1068,"USUBJID":"PSIVISSIG0002_1068","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21834,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1069,"USUBJID":"PSIVISSIG0002_1069","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82615,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1070,"USUBJID":"PSIVISSIG0002_1070","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.9384,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1071,"USUBJID":"PSIVISSIG0002_1071","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0397,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1072,"USUBJID":"PSIVISSIG0002_1072","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.16085,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1073,"USUBJID":"PSIVISSIG0002_1073","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.69473,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1074,"USUBJID":"PSIVISSIG0002_1074","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.0089,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1075,"USUBJID":"PSIVISSIG0002_1075","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.91992,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1076,"USUBJID":"PSIVISSIG0002_1076","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65435,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1077,"USUBJID":"PSIVISSIG0002_1077","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.14648,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1078,"USUBJID":"PSIVISSIG0002_1078","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0616,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1079,"USUBJID":"PSIVISSIG0002_1079","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68378,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1080,"USUBJID":"PSIVISSIG0002_1080","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.17248,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1081,"USUBJID":"PSIVISSIG0002_1081","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.37098,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1082,"USUBJID":"PSIVISSIG0002_1082","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.35455,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1083,"USUBJID":"PSIVISSIG0002_1083","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.54483,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1084,"USUBJID":"PSIVISSIG0002_1084","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.01437,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1085,"USUBJID":"PSIVISSIG0002_1085","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82957,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1086,"USUBJID":"PSIVISSIG0002_1086","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23477,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1087,"USUBJID":"PSIVISSIG0002_1087","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.34428,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1088,"USUBJID":"PSIVISSIG0002_1088","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.08282,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1089,"USUBJID":"PSIVISSIG0002_1089","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17933,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1090,"USUBJID":"PSIVISSIG0002_1090","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19028,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1091,"USUBJID":"PSIVISSIG0002_1091","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42916,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1092,"USUBJID":"PSIVISSIG0002_1092","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19302,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1093,"USUBJID":"PSIVISSIG0002_1093","AGE":77,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.27858,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1094,"USUBJID":"PSIVISSIG0002_1094","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19576,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1095,"USUBJID":"PSIVISSIG0002_1095","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.68857,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1096,"USUBJID":"PSIVISSIG0002_1096","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08693,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1097,"USUBJID":"PSIVISSIG0002_1097","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.18412,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1098,"USUBJID":"PSIVISSIG0002_1098","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97878,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1099,"USUBJID":"PSIVISSIG0002_1099","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96509,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1100,"USUBJID":"PSIVISSIG0002_1100","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.87953,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1101,"USUBJID":"PSIVISSIG0002_1101","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94935,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1102,"USUBJID":"PSIVISSIG0002_1102","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42642,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1103,"USUBJID":"PSIVISSIG0002_1103","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79398,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1104,"USUBJID":"PSIVISSIG0002_1104","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.29432,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1105,"USUBJID":"PSIVISSIG0002_1105","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87885,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1106,"USUBJID":"PSIVISSIG0002_1106","AGE":44,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.09788,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1107,"USUBJID":"PSIVISSIG0002_1107","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.57016,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1108,"USUBJID":"PSIVISSIG0002_1108","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57426,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1109,"USUBJID":"PSIVISSIG0002_1109","AGE":53,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.59617,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1110,"USUBJID":"PSIVISSIG0002_1110","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66256,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1111,"USUBJID":"PSIVISSIG0002_1111","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.09514,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1112,"USUBJID":"PSIVISSIG0002_1112","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69815,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1113,"USUBJID":"PSIVISSIG0002_1113","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7885,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1114,"USUBJID":"PSIVISSIG0002_1114","AGE":80,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.73922,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1115,"USUBJID":"PSIVISSIG0002_1115","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.27584,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1116,"USUBJID":"PSIVISSIG0002_1116","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93361,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1117,"USUBJID":"PSIVISSIG0002_1117","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68104,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1118,"USUBJID":"PSIVISSIG0002_1118","AGE":84,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.43395,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1119,"USUBJID":"PSIVISSIG0002_1119","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05339,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1120,"USUBJID":"PSIVISSIG0002_1120","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04654,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1121,"USUBJID":"PSIVISSIG0002_1121","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10335,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1122,"USUBJID":"PSIVISSIG0002_1122","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42094,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1123,"USUBJID":"PSIVISSIG0002_1123","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.01232,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1124,"USUBJID":"PSIVISSIG0002_1124","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.73169,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1125,"USUBJID":"PSIVISSIG0002_1125","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.87885,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1126,"USUBJID":"PSIVISSIG0002_1126","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.45038,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1127,"USUBJID":"PSIVISSIG0002_1127","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48665,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1128,"USUBJID":"PSIVISSIG0002_1128","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.37166,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1129,"USUBJID":"PSIVISSIG0002_1129","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.30322,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1130,"USUBJID":"PSIVISSIG0002_1130","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.78439,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1131,"USUBJID":"PSIVISSIG0002_1131","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.60575,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1132,"USUBJID":"PSIVISSIG0002_1132","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.87953,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1133,"USUBJID":"PSIVISSIG0002_1133","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.6653,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1134,"USUBJID":"PSIVISSIG0002_1134","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.09514,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1135,"USUBJID":"PSIVISSIG0002_1135","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96783,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1136,"USUBJID":"PSIVISSIG0002_1136","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.26899,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1137,"USUBJID":"PSIVISSIG0002_1137","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94661,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1138,"USUBJID":"PSIVISSIG0002_1138","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69815,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1139,"USUBJID":"PSIVISSIG0002_1139","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.02669,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1140,"USUBJID":"PSIVISSIG0002_1140","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.36413,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1141,"USUBJID":"PSIVISSIG0002_1141","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.17454,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1142,"USUBJID":"PSIVISSIG0002_1142","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.44216,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1143,"USUBJID":"PSIVISSIG0002_1143","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97057,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1144,"USUBJID":"PSIVISSIG0002_1144","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.1499,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1145,"USUBJID":"PSIVISSIG0002_1145","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.43121,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1146,"USUBJID":"PSIVISSIG0002_1146","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.50582,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1147,"USUBJID":"PSIVISSIG0002_1147","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35318,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1148,"USUBJID":"PSIVISSIG0002_1148","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85147,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1149,"USUBJID":"PSIVISSIG0002_1149","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17659,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1150,"USUBJID":"PSIVISSIG0002_1150","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.85079,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1151,"USUBJID":"PSIVISSIG0002_1151","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.13347,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1152,"USUBJID":"PSIVISSIG0002_1152","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.37509,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1153,"USUBJID":"PSIVISSIG0002_1153","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34908,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1154,"USUBJID":"PSIVISSIG0002_1154","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35318,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1155,"USUBJID":"PSIVISSIG0002_1155","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.88775,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1156,"USUBJID":"PSIVISSIG0002_1156","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0397,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1157,"USUBJID":"PSIVISSIG0002_1157","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.77139,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1158,"USUBJID":"PSIVISSIG0002_1158","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.99521,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1159,"USUBJID":"PSIVISSIG0002_1159","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68446,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1160,"USUBJID":"PSIVISSIG0002_1160","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.38809,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1161,"USUBJID":"PSIVISSIG0002_1161","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28131,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1162,"USUBJID":"PSIVISSIG0002_1162","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.11294,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1163,"USUBJID":"PSIVISSIG0002_1163","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.27652,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1164,"USUBJID":"PSIVISSIG0002_1164","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.27173,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1165,"USUBJID":"PSIVISSIG0002_1165","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68378,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1166,"USUBJID":"PSIVISSIG0002_1166","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17933,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1167,"USUBJID":"PSIVISSIG0002_1167","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.31143,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1168,"USUBJID":"PSIVISSIG0002_1168","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.1937,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1169,"USUBJID":"PSIVISSIG0002_1169","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.44285,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1170,"USUBJID":"PSIVISSIG0002_1170","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.89528,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1171,"USUBJID":"PSIVISSIG0002_1171","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.66461,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1172,"USUBJID":"PSIVISSIG0002_1172","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.06297,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1173,"USUBJID":"PSIVISSIG0002_1173","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.18823,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1174,"USUBJID":"PSIVISSIG0002_1174","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33949,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1175,"USUBJID":"PSIVISSIG0002_1175","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.9076,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1176,"USUBJID":"PSIVISSIG0002_1176","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.1896,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1177,"USUBJID":"PSIVISSIG0002_1177","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.90281,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1178,"USUBJID":"PSIVISSIG0002_1178","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21013,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1179,"USUBJID":"PSIVISSIG0002_1179","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.22793,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1180,"USUBJID":"PSIVISSIG0002_1180","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.62628,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1181,"USUBJID":"PSIVISSIG0002_1181","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04107,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1182,"USUBJID":"PSIVISSIG0002_1182","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.16906,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1183,"USUBJID":"PSIVISSIG0002_1183","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.89391,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1184,"USUBJID":"PSIVISSIG0002_1184","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49966,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1185,"USUBJID":"PSIVISSIG0002_1185","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28953,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1186,"USUBJID":"PSIVISSIG0002_1186","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.05133,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1187,"USUBJID":"PSIVISSIG0002_1187","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40178,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1188,"USUBJID":"PSIVISSIG0002_1188","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.40315,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1189,"USUBJID":"PSIVISSIG0002_1189","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.1499,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1190,"USUBJID":"PSIVISSIG0002_1190","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80219,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1191,"USUBJID":"PSIVISSIG0002_1191","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.14921,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1192,"USUBJID":"PSIVISSIG0002_1192","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.15195,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1193,"USUBJID":"PSIVISSIG0002_1193","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.99247,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1194,"USUBJID":"PSIVISSIG0002_1194","AGE":82,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40726,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1195,"USUBJID":"PSIVISSIG0002_1195","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.295,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1196,"USUBJID":"PSIVISSIG0002_1196","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.3614,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1197,"USUBJID":"PSIVISSIG0002_1197","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.17317,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1198,"USUBJID":"PSIVISSIG0002_1198","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87337,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1199,"USUBJID":"PSIVISSIG0002_1199","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.31896,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1200,"USUBJID":"PSIVISSIG0002_1200","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.18823,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1201,"USUBJID":"PSIVISSIG0002_1201","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.20055,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1202,"USUBJID":"PSIVISSIG0002_1202","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.93292,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1203,"USUBJID":"PSIVISSIG0002_1203","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65161,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1204,"USUBJID":"PSIVISSIG0002_1204","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.83915,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1205,"USUBJID":"PSIVISSIG0002_1205","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.81246,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1206,"USUBJID":"PSIVISSIG0002_1206","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65982,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1207,"USUBJID":"PSIVISSIG0002_1207","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42094,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1208,"USUBJID":"PSIVISSIG0002_1208","AGE":82,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.39083,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1209,"USUBJID":"PSIVISSIG0002_1209","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72211,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1210,"USUBJID":"PSIVISSIG0002_1210","AGE":44,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11704,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1211,"USUBJID":"PSIVISSIG0002_1211","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.39904,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1212,"USUBJID":"PSIVISSIG0002_1212","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.4011,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1213,"USUBJID":"PSIVISSIG0002_1213","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.14237,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1214,"USUBJID":"PSIVISSIG0002_1214","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.24983,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1215,"USUBJID":"PSIVISSIG0002_1215","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23203,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1216,"USUBJID":"PSIVISSIG0002_1216","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.1718,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1217,"USUBJID":"PSIVISSIG0002_1217","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.55373,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1218,"USUBJID":"PSIVISSIG0002_1218","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.38467,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1219,"USUBJID":"PSIVISSIG0002_1219","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.68172,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1220,"USUBJID":"PSIVISSIG0002_1220","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.6961,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1221,"USUBJID":"PSIVISSIG0002_1221","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00958,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1222,"USUBJID":"PSIVISSIG0002_1222","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.64819,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1223,"USUBJID":"PSIVISSIG0002_1223","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.5373,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1224,"USUBJID":"PSIVISSIG0002_1224","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47775,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1225,"USUBJID":"PSIVISSIG0002_1225","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72553,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1226,"USUBJID":"PSIVISSIG0002_1226","AGE":81,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81451,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1227,"USUBJID":"PSIVISSIG0002_1227","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72005,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1228,"USUBJID":"PSIVISSIG0002_1228","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21834,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1229,"USUBJID":"PSIVISSIG0002_1229","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.2115,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1230,"USUBJID":"PSIVISSIG0002_1230","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.01848,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1231,"USUBJID":"PSIVISSIG0002_1231","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.79261,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1232,"USUBJID":"PSIVISSIG0002_1232","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.94182,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1233,"USUBJID":"PSIVISSIG0002_1233","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87337,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1234,"USUBJID":"PSIVISSIG0002_1234","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.99658,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1235,"USUBJID":"PSIVISSIG0002_1235","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78576,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1236,"USUBJID":"PSIVISSIG0002_1236","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04654,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1237,"USUBJID":"PSIVISSIG0002_1237","AGE":44,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.53662,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1238,"USUBJID":"PSIVISSIG0002_1238","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.86858,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1239,"USUBJID":"PSIVISSIG0002_1239","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.61123,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1240,"USUBJID":"PSIVISSIG0002_1240","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28405,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1241,"USUBJID":"PSIVISSIG0002_1241","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11978,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1242,"USUBJID":"PSIVISSIG0002_1242","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.84942,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1243,"USUBJID":"PSIVISSIG0002_1243","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11157,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1244,"USUBJID":"PSIVISSIG0002_1244","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.98973,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1245,"USUBJID":"PSIVISSIG0002_1245","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.04381,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1246,"USUBJID":"PSIVISSIG0002_1246","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.14442,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1247,"USUBJID":"PSIVISSIG0002_1247","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70294,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1248,"USUBJID":"PSIVISSIG0002_1248","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.2553,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1249,"USUBJID":"PSIVISSIG0002_1249","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48665,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1250,"USUBJID":"PSIVISSIG0002_1250","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.98973,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1251,"USUBJID":"PSIVISSIG0002_1251","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.02122,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1252,"USUBJID":"PSIVISSIG0002_1252","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.48871,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1253,"USUBJID":"PSIVISSIG0002_1253","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.67214,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1254,"USUBJID":"PSIVISSIG0002_1254","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85147,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1255,"USUBJID":"PSIVISSIG0002_1255","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81177,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1256,"USUBJID":"PSIVISSIG0002_1256","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.9692,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1257,"USUBJID":"PSIVISSIG0002_1257","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.41821,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1258,"USUBJID":"PSIVISSIG0002_1258","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.8501,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1259,"USUBJID":"PSIVISSIG0002_1259","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.03491,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1260,"USUBJID":"PSIVISSIG0002_1260","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.2204,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1261,"USUBJID":"PSIVISSIG0002_1261","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70294,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1262,"USUBJID":"PSIVISSIG0002_1262","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.18891,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1263,"USUBJID":"PSIVISSIG0002_1263","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81725,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1264,"USUBJID":"PSIVISSIG0002_1264","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61259,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1265,"USUBJID":"PSIVISSIG0002_1265","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25667,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1266,"USUBJID":"PSIVISSIG0002_1266","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.31964,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1267,"USUBJID":"PSIVISSIG0002_1267","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.50376,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1268,"USUBJID":"PSIVISSIG0002_1268","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23751,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1269,"USUBJID":"PSIVISSIG0002_1269","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11431,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1270,"USUBJID":"PSIVISSIG0002_1270","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.35524,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1271,"USUBJID":"PSIVISSIG0002_1271","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.40246,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1272,"USUBJID":"PSIVISSIG0002_1272","AGE":68,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.95483,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1273,"USUBJID":"PSIVISSIG0002_1273","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.80561,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1274,"USUBJID":"PSIVISSIG0002_1274","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.96099,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1275,"USUBJID":"PSIVISSIG0002_1275","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.89049,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1276,"USUBJID":"PSIVISSIG0002_1276","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4538,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1277,"USUBJID":"PSIVISSIG0002_1277","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.99452,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1278,"USUBJID":"PSIVISSIG0002_1278","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.86448,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1279,"USUBJID":"PSIVISSIG0002_1279","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20123,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1280,"USUBJID":"PSIVISSIG0002_1280","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05339,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1281,"USUBJID":"PSIVISSIG0002_1281","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.32923,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1282,"USUBJID":"PSIVISSIG0002_1282","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56331,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1283,"USUBJID":"PSIVISSIG0002_1283","AGE":48,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.13142,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1284,"USUBJID":"PSIVISSIG0002_1284","AGE":43,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49008,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1285,"USUBJID":"PSIVISSIG0002_1285","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51403,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1286,"USUBJID":"PSIVISSIG0002_1286","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4319,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1287,"USUBJID":"PSIVISSIG0002_1287","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.26899,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1288,"USUBJID":"PSIVISSIG0002_1288","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.77892,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1289,"USUBJID":"PSIVISSIG0002_1289","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12526,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1290,"USUBJID":"PSIVISSIG0002_1290","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.35181,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1291,"USUBJID":"PSIVISSIG0002_1291","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.21492,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1292,"USUBJID":"PSIVISSIG0002_1292","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84805,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1293,"USUBJID":"PSIVISSIG0002_1293","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.96099,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1294,"USUBJID":"PSIVISSIG0002_1294","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79671,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1295,"USUBJID":"PSIVISSIG0002_1295","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82409,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1296,"USUBJID":"PSIVISSIG0002_1296","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.5729,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1297,"USUBJID":"PSIVISSIG0002_1297","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9473,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1298,"USUBJID":"PSIVISSIG0002_1298","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.83984,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1299,"USUBJID":"PSIVISSIG0002_1299","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10062,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1300,"USUBJID":"PSIVISSIG0002_1300","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62697,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1301,"USUBJID":"PSIVISSIG0002_1301","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.09925,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1302,"USUBJID":"PSIVISSIG0002_1302","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35866,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1303,"USUBJID":"PSIVISSIG0002_1303","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.92813,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1304,"USUBJID":"PSIVISSIG0002_1304","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.32717,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1305,"USUBJID":"PSIVISSIG0002_1305","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.8104,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1306,"USUBJID":"PSIVISSIG0002_1306","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87611,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1307,"USUBJID":"PSIVISSIG0002_1307","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57153,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1308,"USUBJID":"PSIVISSIG0002_1308","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.76044,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1309,"USUBJID":"PSIVISSIG0002_1309","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.65366,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1310,"USUBJID":"PSIVISSIG0002_1310","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02053,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1311,"USUBJID":"PSIVISSIG0002_1311","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.66735,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1312,"USUBJID":"PSIVISSIG0002_1312","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68378,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1313,"USUBJID":"PSIVISSIG0002_1313","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.33676,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1314,"USUBJID":"PSIVISSIG0002_1314","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.30048,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1315,"USUBJID":"PSIVISSIG0002_1315","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.53046,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1316,"USUBJID":"PSIVISSIG0002_1316","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.09993,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1317,"USUBJID":"PSIVISSIG0002_1317","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.68036,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1318,"USUBJID":"PSIVISSIG0002_1318","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.10198,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1319,"USUBJID":"PSIVISSIG0002_1319","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.36687,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1320,"USUBJID":"PSIVISSIG0002_1320","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33539,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1321,"USUBJID":"PSIVISSIG0002_1321","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.2115,"CNSR":1,"EVNTDESC":"Second next-line therapy initiated","CNSDTDSC":"Censored at the end date of the next-line therapy","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1322,"USUBJID":"PSIVISSIG0002_1322","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.12047,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1323,"USUBJID":"PSIVISSIG0002_1323","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.03696,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1324,"USUBJID":"PSIVISSIG0002_1324","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11704,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1325,"USUBJID":"PSIVISSIG0002_1325","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.50513,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1326,"USUBJID":"PSIVISSIG0002_1326","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81177,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1327,"USUBJID":"PSIVISSIG0002_1327","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.08487,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1328,"USUBJID":"PSIVISSIG0002_1328","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79124,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1329,"USUBJID":"PSIVISSIG0002_1329","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6783,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1330,"USUBJID":"PSIVISSIG0002_1330","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.07255,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1331,"USUBJID":"PSIVISSIG0002_1331","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20945,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1332,"USUBJID":"PSIVISSIG0002_1332","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.98152,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1333,"USUBJID":"PSIVISSIG0002_1333","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.78713,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1334,"USUBJID":"PSIVISSIG0002_1334","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.86448,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1335,"USUBJID":"PSIVISSIG0002_1335","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56331,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1336,"USUBJID":"PSIVISSIG0002_1336","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.71458,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1337,"USUBJID":"PSIVISSIG0002_1337","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.16564,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1338,"USUBJID":"PSIVISSIG0002_1338","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49418,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1339,"USUBJID":"PSIVISSIG0002_1339","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.23888,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1340,"USUBJID":"PSIVISSIG0002_1340","AGE":32,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65161,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1341,"USUBJID":"PSIVISSIG0002_1341","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.31417,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1342,"USUBJID":"PSIVISSIG0002_1342","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.53183,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1343,"USUBJID":"PSIVISSIG0002_1343","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94387,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1344,"USUBJID":"PSIVISSIG0002_1344","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54415,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1345,"USUBJID":"PSIVISSIG0002_1345","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56331,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1346,"USUBJID":"PSIVISSIG0002_1346","AGE":35,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.79329,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1347,"USUBJID":"PSIVISSIG0002_1347","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.99658,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1348,"USUBJID":"PSIVISSIG0002_1348","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08693,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1349,"USUBJID":"PSIVISSIG0002_1349","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68994,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1350,"USUBJID":"PSIVISSIG0002_1350","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34086,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1351,"USUBJID":"PSIVISSIG0002_1351","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.45585,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1352,"USUBJID":"PSIVISSIG0002_1352","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.90897,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1353,"USUBJID":"PSIVISSIG0002_1353","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.56468,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1354,"USUBJID":"PSIVISSIG0002_1354","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.32033,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1355,"USUBJID":"PSIVISSIG0002_1355","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82409,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1356,"USUBJID":"PSIVISSIG0002_1356","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.39973,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1357,"USUBJID":"PSIVISSIG0002_1357","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.62765,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1358,"USUBJID":"PSIVISSIG0002_1358","AGE":84,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.43669,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1359,"USUBJID":"PSIVISSIG0002_1359","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.99316,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1360,"USUBJID":"PSIVISSIG0002_1360","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85695,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1361,"USUBJID":"PSIVISSIG0002_1361","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49692,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1362,"USUBJID":"PSIVISSIG0002_1362","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.96441,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1363,"USUBJID":"PSIVISSIG0002_1363","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.76797,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1364,"USUBJID":"PSIVISSIG0002_1364","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11704,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1365,"USUBJID":"PSIVISSIG0002_1365","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95003,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1366,"USUBJID":"PSIVISSIG0002_1366","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0835,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1367,"USUBJID":"PSIVISSIG0002_1367","AGE":78,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72758,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1368,"USUBJID":"PSIVISSIG0002_1368","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.90349,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1369,"USUBJID":"PSIVISSIG0002_1369","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.18686,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1370,"USUBJID":"PSIVISSIG0002_1370","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61533,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1371,"USUBJID":"PSIVISSIG0002_1371","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68172,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1372,"USUBJID":"PSIVISSIG0002_1372","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02327,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1373,"USUBJID":"PSIVISSIG0002_1373","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.31006,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1374,"USUBJID":"PSIVISSIG0002_1374","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.86721,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1375,"USUBJID":"PSIVISSIG0002_1375","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.77139,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1376,"USUBJID":"PSIVISSIG0002_1376","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17933,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1377,"USUBJID":"PSIVISSIG0002_1377","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.35181,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1378,"USUBJID":"PSIVISSIG0002_1378","AGE":78,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33265,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1379,"USUBJID":"PSIVISSIG0002_1379","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.12457,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1380,"USUBJID":"PSIVISSIG0002_1380","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51677,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1381,"USUBJID":"PSIVISSIG0002_1381","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.75291,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1382,"USUBJID":"PSIVISSIG0002_1382","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.8063,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1383,"USUBJID":"PSIVISSIG0002_1383","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36277,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1384,"USUBJID":"PSIVISSIG0002_1384","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.90212,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1385,"USUBJID":"PSIVISSIG0002_1385","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96783,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1386,"USUBJID":"PSIVISSIG0002_1386","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82683,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1387,"USUBJID":"PSIVISSIG0002_1387","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.43737,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1388,"USUBJID":"PSIVISSIG0002_1388","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.32717,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1389,"USUBJID":"PSIVISSIG0002_1389","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64339,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1390,"USUBJID":"PSIVISSIG0002_1390","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.72964,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1391,"USUBJID":"PSIVISSIG0002_1391","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.98631,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1392,"USUBJID":"PSIVISSIG0002_1392","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35318,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1393,"USUBJID":"PSIVISSIG0002_1393","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.39014,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1394,"USUBJID":"PSIVISSIG0002_1394","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63244,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1395,"USUBJID":"PSIVISSIG0002_1395","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.3614,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1396,"USUBJID":"PSIVISSIG0002_1396","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81862,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1397,"USUBJID":"PSIVISSIG0002_1397","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00137,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1398,"USUBJID":"PSIVISSIG0002_1398","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.59069,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1399,"USUBJID":"PSIVISSIG0002_1399","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.38877,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1400,"USUBJID":"PSIVISSIG0002_1400","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.60712,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1401,"USUBJID":"PSIVISSIG0002_1401","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72485,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1402,"USUBJID":"PSIVISSIG0002_1402","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72279,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1403,"USUBJID":"PSIVISSIG0002_1403","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.89391,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1404,"USUBJID":"PSIVISSIG0002_1404","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04244,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1405,"USUBJID":"PSIVISSIG0002_1405","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97604,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1406,"USUBJID":"PSIVISSIG0002_1406","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.93292,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1407,"USUBJID":"PSIVISSIG0002_1407","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68378,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1408,"USUBJID":"PSIVISSIG0002_1408","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56057,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1409,"USUBJID":"PSIVISSIG0002_1409","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11704,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1410,"USUBJID":"PSIVISSIG0002_1410","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.93703,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1411,"USUBJID":"PSIVISSIG0002_1411","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0178,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1412,"USUBJID":"PSIVISSIG0002_1412","AGE":78,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33539,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1413,"USUBJID":"PSIVISSIG0002_1413","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.295,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1414,"USUBJID":"PSIVISSIG0002_1414","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.08761,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1415,"USUBJID":"PSIVISSIG0002_1415","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.46817,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1416,"USUBJID":"PSIVISSIG0002_1416","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.58658,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1417,"USUBJID":"PSIVISSIG0002_1417","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.71732,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1418,"USUBJID":"PSIVISSIG0002_1418","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.40589,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1419,"USUBJID":"PSIVISSIG0002_1419","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25667,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1420,"USUBJID":"PSIVISSIG0002_1420","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.65298,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1421,"USUBJID":"PSIVISSIG0002_1421","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19849,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1422,"USUBJID":"PSIVISSIG0002_1422","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.58453,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1423,"USUBJID":"PSIVISSIG0002_1423","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36824,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1424,"USUBJID":"PSIVISSIG0002_1424","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68378,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1425,"USUBJID":"PSIVISSIG0002_1425","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84257,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1426,"USUBJID":"PSIVISSIG0002_1426","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.92813,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1427,"USUBJID":"PSIVISSIG0002_1427","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19849,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1428,"USUBJID":"PSIVISSIG0002_1428","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.91992,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1429,"USUBJID":"PSIVISSIG0002_1429","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.74401,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1430,"USUBJID":"PSIVISSIG0002_1430","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9473,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1431,"USUBJID":"PSIVISSIG0002_1431","AGE":77,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.09514,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1432,"USUBJID":"PSIVISSIG0002_1432","AGE":83,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10335,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1433,"USUBJID":"PSIVISSIG0002_1433","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65982,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1434,"USUBJID":"PSIVISSIG0002_1434","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.71663,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1435,"USUBJID":"PSIVISSIG0002_1435","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.25873,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1436,"USUBJID":"PSIVISSIG0002_1436","AGE":44,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.51745,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1437,"USUBJID":"PSIVISSIG0002_1437","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.70705,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1438,"USUBJID":"PSIVISSIG0002_1438","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.28884,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1439,"USUBJID":"PSIVISSIG0002_1439","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.43532,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1440,"USUBJID":"PSIVISSIG0002_1440","AGE":25,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.16016,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1441,"USUBJID":"PSIVISSIG0002_1441","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.99589,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1442,"USUBJID":"PSIVISSIG0002_1442","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.04038,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1443,"USUBJID":"PSIVISSIG0002_1443","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.36619,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1444,"USUBJID":"PSIVISSIG0002_1444","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9117,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1445,"USUBJID":"PSIVISSIG0002_1445","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.86379,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1446,"USUBJID":"PSIVISSIG0002_1446","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.86995,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1447,"USUBJID":"PSIVISSIG0002_1447","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.52772,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1448,"USUBJID":"PSIVISSIG0002_1448","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.94456,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1449,"USUBJID":"PSIVISSIG0002_1449","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.20739,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1450,"USUBJID":"PSIVISSIG0002_1450","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.58658,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1451,"USUBJID":"PSIVISSIG0002_1451","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.3655,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1452,"USUBJID":"PSIVISSIG0002_1452","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.2601,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1453,"USUBJID":"PSIVISSIG0002_1453","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.32238,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1454,"USUBJID":"PSIVISSIG0002_1454","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6345,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1455,"USUBJID":"PSIVISSIG0002_1455","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19576,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1456,"USUBJID":"PSIVISSIG0002_1456","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05886,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1457,"USUBJID":"PSIVISSIG0002_1457","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85695,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1458,"USUBJID":"PSIVISSIG0002_1458","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.53799,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1459,"USUBJID":"PSIVISSIG0002_1459","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94114,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1460,"USUBJID":"PSIVISSIG0002_1460","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.97262,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1461,"USUBJID":"PSIVISSIG0002_1461","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.11499,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1462,"USUBJID":"PSIVISSIG0002_1462","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.78782,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1463,"USUBJID":"PSIVISSIG0002_1463","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.31417,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1464,"USUBJID":"PSIVISSIG0002_1464","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.14648,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1465,"USUBJID":"PSIVISSIG0002_1465","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.95962,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1466,"USUBJID":"PSIVISSIG0002_1466","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26489,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1467,"USUBJID":"PSIVISSIG0002_1467","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.91376,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1468,"USUBJID":"PSIVISSIG0002_1468","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49966,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1469,"USUBJID":"PSIVISSIG0002_1469","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.55305,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1470,"USUBJID":"PSIVISSIG0002_1470","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.29021,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1471,"USUBJID":"PSIVISSIG0002_1471","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.84668,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1472,"USUBJID":"PSIVISSIG0002_1472","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.28747,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1473,"USUBJID":"PSIVISSIG0002_1473","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.32991,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1474,"USUBJID":"PSIVISSIG0002_1474","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.9384,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1475,"USUBJID":"PSIVISSIG0002_1475","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.74743,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1476,"USUBJID":"PSIVISSIG0002_1476","AGE":39,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.11704,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1477,"USUBJID":"PSIVISSIG0002_1477","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.89322,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1478,"USUBJID":"PSIVISSIG0002_1478","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.45859,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1479,"USUBJID":"PSIVISSIG0002_1479","AGE":89,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4538,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1480,"USUBJID":"PSIVISSIG0002_1480","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80493,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1481,"USUBJID":"PSIVISSIG0002_1481","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87885,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1482,"USUBJID":"PSIVISSIG0002_1482","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.89185,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1483,"USUBJID":"PSIVISSIG0002_1483","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.74196,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1484,"USUBJID":"PSIVISSIG0002_1484","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62149,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1485,"USUBJID":"PSIVISSIG0002_1485","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.70705,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1486,"USUBJID":"PSIVISSIG0002_1486","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.18823,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1487,"USUBJID":"PSIVISSIG0002_1487","AGE":44,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.52841,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1488,"USUBJID":"PSIVISSIG0002_1488","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62149,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1489,"USUBJID":"PSIVISSIG0002_1489","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.0486,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1490,"USUBJID":"PSIVISSIG0002_1490","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51745,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1491,"USUBJID":"PSIVISSIG0002_1491","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.46954,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1492,"USUBJID":"PSIVISSIG0002_1492","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.13005,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1493,"USUBJID":"PSIVISSIG0002_1493","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47775,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1494,"USUBJID":"PSIVISSIG0002_1494","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.50513,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1495,"USUBJID":"PSIVISSIG0002_1495","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.86242,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1496,"USUBJID":"PSIVISSIG0002_1496","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.22861,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1497,"USUBJID":"PSIVISSIG0002_1497","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.48871,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1498,"USUBJID":"PSIVISSIG0002_1498","AGE":83,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.13895,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1499,"USUBJID":"PSIVISSIG0002_1499","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.53457,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1500,"USUBJID":"PSIVISSIG0002_1500","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.08214,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1501,"USUBJID":"PSIVISSIG0002_1501","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64613,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1502,"USUBJID":"PSIVISSIG0002_1502","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52019,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1503,"USUBJID":"PSIVISSIG0002_1503","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.19097,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1504,"USUBJID":"PSIVISSIG0002_1504","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49281,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1505,"USUBJID":"PSIVISSIG0002_1505","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97331,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1506,"USUBJID":"PSIVISSIG0002_1506","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.52225,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1507,"USUBJID":"PSIVISSIG0002_1507","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.30322,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1508,"USUBJID":"PSIVISSIG0002_1508","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42094,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1509,"USUBJID":"PSIVISSIG0002_1509","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.30869,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1510,"USUBJID":"PSIVISSIG0002_1510","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.29843,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1511,"USUBJID":"PSIVISSIG0002_1511","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9911,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1512,"USUBJID":"PSIVISSIG0002_1512","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35318,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1513,"USUBJID":"PSIVISSIG0002_1513","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00958,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1514,"USUBJID":"PSIVISSIG0002_1514","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51472,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1515,"USUBJID":"PSIVISSIG0002_1515","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21013,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1516,"USUBJID":"PSIVISSIG0002_1516","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.19986,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1517,"USUBJID":"PSIVISSIG0002_1517","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.56194,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1518,"USUBJID":"PSIVISSIG0002_1518","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.09309,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1519,"USUBJID":"PSIVISSIG0002_1519","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.27584,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1520,"USUBJID":"PSIVISSIG0002_1520","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.67762,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1521,"USUBJID":"PSIVISSIG0002_1521","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.38398,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1522,"USUBJID":"PSIVISSIG0002_1522","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23477,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1523,"USUBJID":"PSIVISSIG0002_1523","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24846,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1524,"USUBJID":"PSIVISSIG0002_1524","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.89459,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1525,"USUBJID":"PSIVISSIG0002_1525","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.63997,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1526,"USUBJID":"PSIVISSIG0002_1526","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.09309,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1527,"USUBJID":"PSIVISSIG0002_1527","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.40794,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1528,"USUBJID":"PSIVISSIG0002_1528","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.18617,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1529,"USUBJID":"PSIVISSIG0002_1529","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.91102,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1530,"USUBJID":"PSIVISSIG0002_1530","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57974,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1531,"USUBJID":"PSIVISSIG0002_1531","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.77413,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1532,"USUBJID":"PSIVISSIG0002_1532","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33812,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1533,"USUBJID":"PSIVISSIG0002_1533","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.22313,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1534,"USUBJID":"PSIVISSIG0002_1534","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.62355,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1535,"USUBJID":"PSIVISSIG0002_1535","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95551,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1536,"USUBJID":"PSIVISSIG0002_1536","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51472,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1537,"USUBJID":"PSIVISSIG0002_1537","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.34223,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1538,"USUBJID":"PSIVISSIG0002_1538","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.1629,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1539,"USUBJID":"PSIVISSIG0002_1539","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.96372,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1540,"USUBJID":"PSIVISSIG0002_1540","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.85352,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1541,"USUBJID":"PSIVISSIG0002_1541","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.22245,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1542,"USUBJID":"PSIVISSIG0002_1542","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72485,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1543,"USUBJID":"PSIVISSIG0002_1543","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.34771,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1544,"USUBJID":"PSIVISSIG0002_1544","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.1848,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1545,"USUBJID":"PSIVISSIG0002_1545","AGE":88,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95825,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1546,"USUBJID":"PSIVISSIG0002_1546","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.987,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1547,"USUBJID":"PSIVISSIG0002_1547","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.64339,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1548,"USUBJID":"PSIVISSIG0002_1548","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.41068,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1549,"USUBJID":"PSIVISSIG0002_1549","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.18891,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1550,"USUBJID":"PSIVISSIG0002_1550","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.06982,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1551,"USUBJID":"PSIVISSIG0002_1551","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.13826,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1552,"USUBJID":"PSIVISSIG0002_1552","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.85352,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1553,"USUBJID":"PSIVISSIG0002_1553","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81314,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1554,"USUBJID":"PSIVISSIG0002_1554","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95277,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1555,"USUBJID":"PSIVISSIG0002_1555","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.20602,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1556,"USUBJID":"PSIVISSIG0002_1556","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.69131,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1557,"USUBJID":"PSIVISSIG0002_1557","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.94182,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1558,"USUBJID":"PSIVISSIG0002_1558","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.12663,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1559,"USUBJID":"PSIVISSIG0002_1559","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.9076,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1560,"USUBJID":"PSIVISSIG0002_1560","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.06502,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1561,"USUBJID":"PSIVISSIG0002_1561","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26489,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1562,"USUBJID":"PSIVISSIG0002_1562","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.73648,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1563,"USUBJID":"PSIVISSIG0002_1563","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80493,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1564,"USUBJID":"PSIVISSIG0002_1564","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.65914,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1565,"USUBJID":"PSIVISSIG0002_1565","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66256,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1566,"USUBJID":"PSIVISSIG0002_1566","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.83984,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1567,"USUBJID":"PSIVISSIG0002_1567","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.71663,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1568,"USUBJID":"PSIVISSIG0002_1568","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35866,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1569,"USUBJID":"PSIVISSIG0002_1569","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.76386,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1570,"USUBJID":"PSIVISSIG0002_1570","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.65092,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1571,"USUBJID":"PSIVISSIG0002_1571","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.94524,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1572,"USUBJID":"PSIVISSIG0002_1572","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.18891,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1573,"USUBJID":"PSIVISSIG0002_1573","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61259,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1574,"USUBJID":"PSIVISSIG0002_1574","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.41068,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1575,"USUBJID":"PSIVISSIG0002_1575","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.85284,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1576,"USUBJID":"PSIVISSIG0002_1576","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.32307,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1577,"USUBJID":"PSIVISSIG0002_1577","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.27515,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1578,"USUBJID":"PSIVISSIG0002_1578","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.71526,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1579,"USUBJID":"PSIVISSIG0002_1579","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.10472,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1580,"USUBJID":"PSIVISSIG0002_1580","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.17454,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1581,"USUBJID":"PSIVISSIG0002_1581","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.03491,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1582,"USUBJID":"PSIVISSIG0002_1582","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.31211,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1583,"USUBJID":"PSIVISSIG0002_1583","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.55647,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1584,"USUBJID":"PSIVISSIG0002_1584","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.71526,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1585,"USUBJID":"PSIVISSIG0002_1585","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.0705,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1586,"USUBJID":"PSIVISSIG0002_1586","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72279,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1587,"USUBJID":"PSIVISSIG0002_1587","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.12115,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1588,"USUBJID":"PSIVISSIG0002_1588","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.17112,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1589,"USUBJID":"PSIVISSIG0002_1589","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.84326,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1590,"USUBJID":"PSIVISSIG0002_1590","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04928,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1591,"USUBJID":"PSIVISSIG0002_1591","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33265,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1592,"USUBJID":"PSIVISSIG0002_1592","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.15264,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1593,"USUBJID":"PSIVISSIG0002_1593","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24298,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1594,"USUBJID":"PSIVISSIG0002_1594","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56605,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1595,"USUBJID":"PSIVISSIG0002_1595","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.27789,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1596,"USUBJID":"PSIVISSIG0002_1596","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49418,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1597,"USUBJID":"PSIVISSIG0002_1597","AGE":53,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.3744,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1598,"USUBJID":"PSIVISSIG0002_1598","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69268,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1599,"USUBJID":"PSIVISSIG0002_1599","AGE":77,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08145,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1600,"USUBJID":"PSIVISSIG0002_1600","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.33812,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1601,"USUBJID":"PSIVISSIG0002_1601","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.17248,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1602,"USUBJID":"PSIVISSIG0002_1602","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.54825,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1603,"USUBJID":"PSIVISSIG0002_1603","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.53388,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1604,"USUBJID":"PSIVISSIG0002_1604","AGE":48,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.44627,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1605,"USUBJID":"PSIVISSIG0002_1605","AGE":77,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.295,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1606,"USUBJID":"PSIVISSIG0002_1606","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.42163,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1607,"USUBJID":"PSIVISSIG0002_1607","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48665,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1608,"USUBJID":"PSIVISSIG0002_1608","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.67556,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1609,"USUBJID":"PSIVISSIG0002_1609","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08693,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1610,"USUBJID":"PSIVISSIG0002_1610","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34086,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1611,"USUBJID":"PSIVISSIG0002_1611","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.54825,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1612,"USUBJID":"PSIVISSIG0002_1612","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.73306,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1613,"USUBJID":"PSIVISSIG0002_1613","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.62081,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1614,"USUBJID":"PSIVISSIG0002_1614","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.06776,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1615,"USUBJID":"PSIVISSIG0002_1615","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.2731,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1616,"USUBJID":"PSIVISSIG0002_1616","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10883,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1617,"USUBJID":"PSIVISSIG0002_1617","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35866,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1618,"USUBJID":"PSIVISSIG0002_1618","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.36413,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1619,"USUBJID":"PSIVISSIG0002_1619","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57974,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1620,"USUBJID":"PSIVISSIG0002_1620","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.30048,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1621,"USUBJID":"PSIVISSIG0002_1621","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.29774,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1622,"USUBJID":"PSIVISSIG0002_1622","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.64819,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1623,"USUBJID":"PSIVISSIG0002_1623","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.13826,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1624,"USUBJID":"PSIVISSIG0002_1624","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.52156,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1625,"USUBJID":"PSIVISSIG0002_1625","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.03696,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1626,"USUBJID":"PSIVISSIG0002_1626","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65161,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1627,"USUBJID":"PSIVISSIG0002_1627","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65982,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1628,"USUBJID":"PSIVISSIG0002_1628","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19028,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1629,"USUBJID":"PSIVISSIG0002_1629","AGE":43,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49008,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1630,"USUBJID":"PSIVISSIG0002_1630","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40999,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1631,"USUBJID":"PSIVISSIG0002_1631","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54962,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1632,"USUBJID":"PSIVISSIG0002_1632","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7091,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1633,"USUBJID":"PSIVISSIG0002_1633","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34908,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1634,"USUBJID":"PSIVISSIG0002_1634","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51403,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1635,"USUBJID":"PSIVISSIG0002_1635","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.75154,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1636,"USUBJID":"PSIVISSIG0002_1636","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.99589,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1637,"USUBJID":"PSIVISSIG0002_1637","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85695,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1638,"USUBJID":"PSIVISSIG0002_1638","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.68789,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1639,"USUBJID":"PSIVISSIG0002_1639","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.013,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1640,"USUBJID":"PSIVISSIG0002_1640","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.73306,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1641,"USUBJID":"PSIVISSIG0002_1641","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0178,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1642,"USUBJID":"PSIVISSIG0002_1642","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00137,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1643,"USUBJID":"PSIVISSIG0002_1643","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.26968,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1644,"USUBJID":"PSIVISSIG0002_1644","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21287,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1645,"USUBJID":"PSIVISSIG0002_1645","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.81314,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1646,"USUBJID":"PSIVISSIG0002_1646","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42916,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1647,"USUBJID":"PSIVISSIG0002_1647","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48118,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1648,"USUBJID":"PSIVISSIG0002_1648","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.79808,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1649,"USUBJID":"PSIVISSIG0002_1649","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.06229,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1650,"USUBJID":"PSIVISSIG0002_1650","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65435,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1651,"USUBJID":"PSIVISSIG0002_1651","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.93566,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1652,"USUBJID":"PSIVISSIG0002_1652","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.55989,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1653,"USUBJID":"PSIVISSIG0002_1653","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62971,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1654,"USUBJID":"PSIVISSIG0002_1654","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.08214,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1655,"USUBJID":"PSIVISSIG0002_1655","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.5948,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1656,"USUBJID":"PSIVISSIG0002_1656","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.37372,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1657,"USUBJID":"PSIVISSIG0002_1657","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.3614,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1658,"USUBJID":"PSIVISSIG0002_1658","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.14442,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1659,"USUBJID":"PSIVISSIG0002_1659","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56879,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1660,"USUBJID":"PSIVISSIG0002_1660","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.98836,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1661,"USUBJID":"PSIVISSIG0002_1661","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96235,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1662,"USUBJID":"PSIVISSIG0002_1662","AGE":81,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.79261,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1663,"USUBJID":"PSIVISSIG0002_1663","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6564,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1664,"USUBJID":"PSIVISSIG0002_1664","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.76181,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1665,"USUBJID":"PSIVISSIG0002_1665","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97878,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1666,"USUBJID":"PSIVISSIG0002_1666","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.53799,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1667,"USUBJID":"PSIVISSIG0002_1667","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35318,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1668,"USUBJID":"PSIVISSIG0002_1668","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.68172,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1669,"USUBJID":"PSIVISSIG0002_1669","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63792,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1670,"USUBJID":"PSIVISSIG0002_1670","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.77139,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1671,"USUBJID":"PSIVISSIG0002_1671","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65161,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1672,"USUBJID":"PSIVISSIG0002_1672","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.07392,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1673,"USUBJID":"PSIVISSIG0002_1673","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.67214,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1674,"USUBJID":"PSIVISSIG0002_1674","AGE":53,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.50103,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1675,"USUBJID":"PSIVISSIG0002_1675","AGE":83,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10062,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1676,"USUBJID":"PSIVISSIG0002_1676","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.34839,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1677,"USUBJID":"PSIVISSIG0002_1677","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.39083,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1678,"USUBJID":"PSIVISSIG0002_1678","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.55921,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1679,"USUBJID":"PSIVISSIG0002_1679","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.9384,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1680,"USUBJID":"PSIVISSIG0002_1680","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.27858,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1681,"USUBJID":"PSIVISSIG0002_1681","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.16359,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1682,"USUBJID":"PSIVISSIG0002_1682","AGE":51,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97331,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1683,"USUBJID":"PSIVISSIG0002_1683","AGE":84,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35866,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1684,"USUBJID":"PSIVISSIG0002_1684","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.9911,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1685,"USUBJID":"PSIVISSIG0002_1685","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.08077,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1686,"USUBJID":"PSIVISSIG0002_1686","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34634,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1687,"USUBJID":"PSIVISSIG0002_1687","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.69199,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1688,"USUBJID":"PSIVISSIG0002_1688","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.89185,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1689,"USUBJID":"PSIVISSIG0002_1689","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.46817,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1690,"USUBJID":"PSIVISSIG0002_1690","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.96715,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1691,"USUBJID":"PSIVISSIG0002_1691","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65708,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1692,"USUBJID":"PSIVISSIG0002_1692","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.90075,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1693,"USUBJID":"PSIVISSIG0002_1693","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.41068,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1694,"USUBJID":"PSIVISSIG0002_1694","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.89733,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1695,"USUBJID":"PSIVISSIG0002_1695","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.40657,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1696,"USUBJID":"PSIVISSIG0002_1696","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24025,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1697,"USUBJID":"PSIVISSIG0002_1697","AGE":53,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61807,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1698,"USUBJID":"PSIVISSIG0002_1698","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93908,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1699,"USUBJID":"PSIVISSIG0002_1699","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4319,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1700,"USUBJID":"PSIVISSIG0002_1700","AGE":53,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.37714,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1701,"USUBJID":"PSIVISSIG0002_1701","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.4668,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1702,"USUBJID":"PSIVISSIG0002_1702","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.61602,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1703,"USUBJID":"PSIVISSIG0002_1703","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.63176,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1704,"USUBJID":"PSIVISSIG0002_1704","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.7577,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1705,"USUBJID":"PSIVISSIG0002_1705","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47228,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1706,"USUBJID":"PSIVISSIG0002_1706","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34634,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1707,"USUBJID":"PSIVISSIG0002_1707","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26215,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1708,"USUBJID":"PSIVISSIG0002_1708","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87337,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1709,"USUBJID":"PSIVISSIG0002_1709","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.11773,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1710,"USUBJID":"PSIVISSIG0002_1710","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.51608,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1711,"USUBJID":"PSIVISSIG0002_1711","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.24983,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1712,"USUBJID":"PSIVISSIG0002_1712","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.80561,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1713,"USUBJID":"PSIVISSIG0002_1713","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24572,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1714,"USUBJID":"PSIVISSIG0002_1714","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.295,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1715,"USUBJID":"PSIVISSIG0002_1715","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.30801,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1716,"USUBJID":"PSIVISSIG0002_1716","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7885,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1717,"USUBJID":"PSIVISSIG0002_1717","AGE":53,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.62081,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1718,"USUBJID":"PSIVISSIG0002_1718","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.10951,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1719,"USUBJID":"PSIVISSIG0002_1719","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56605,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1720,"USUBJID":"PSIVISSIG0002_1720","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.95209,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1721,"USUBJID":"PSIVISSIG0002_1721","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.84942,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1722,"USUBJID":"PSIVISSIG0002_1722","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.88912,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1723,"USUBJID":"PSIVISSIG0002_1723","AGE":78,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.7358,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1724,"USUBJID":"PSIVISSIG0002_1724","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.70431,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1725,"USUBJID":"PSIVISSIG0002_1725","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64613,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1726,"USUBJID":"PSIVISSIG0002_1726","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.4271,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1727,"USUBJID":"PSIVISSIG0002_1727","AGE":81,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.77344,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1728,"USUBJID":"PSIVISSIG0002_1728","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.58522,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1729,"USUBJID":"PSIVISSIG0002_1729","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.79877,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1730,"USUBJID":"PSIVISSIG0002_1730","AGE":32,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63244,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1731,"USUBJID":"PSIVISSIG0002_1731","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93908,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1732,"USUBJID":"PSIVISSIG0002_1732","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.68994,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1733,"USUBJID":"PSIVISSIG0002_1733","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20945,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1734,"USUBJID":"PSIVISSIG0002_1734","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.43806,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1735,"USUBJID":"PSIVISSIG0002_1735","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34634,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1736,"USUBJID":"PSIVISSIG0002_1736","AGE":42,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.54483,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1737,"USUBJID":"PSIVISSIG0002_1737","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08693,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1738,"USUBJID":"PSIVISSIG0002_1738","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.85216,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1739,"USUBJID":"PSIVISSIG0002_1739","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.3128,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1740,"USUBJID":"PSIVISSIG0002_1740","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.57016,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1741,"USUBJID":"PSIVISSIG0002_1741","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.73717,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1742,"USUBJID":"PSIVISSIG0002_1742","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.19781,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1743,"USUBJID":"PSIVISSIG0002_1743","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.19781,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1744,"USUBJID":"PSIVISSIG0002_1744","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.9165,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1745,"USUBJID":"PSIVISSIG0002_1745","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.72074,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1746,"USUBJID":"PSIVISSIG0002_1746","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.03422,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1747,"USUBJID":"PSIVISSIG0002_1747","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.90897,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1748,"USUBJID":"PSIVISSIG0002_1748","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.12731,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1749,"USUBJID":"PSIVISSIG0002_1749","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.03696,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1750,"USUBJID":"PSIVISSIG0002_1750","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.24846,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1751,"USUBJID":"PSIVISSIG0002_1751","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67351,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1752,"USUBJID":"PSIVISSIG0002_1752","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.75702,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1753,"USUBJID":"PSIVISSIG0002_1753","AGE":82,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4976,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1754,"USUBJID":"PSIVISSIG0002_1754","AGE":77,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.2512,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1755,"USUBJID":"PSIVISSIG0002_1755","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70294,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1756,"USUBJID":"PSIVISSIG0002_1756","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.69952,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1757,"USUBJID":"PSIVISSIG0002_1757","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.71869,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1758,"USUBJID":"PSIVISSIG0002_1758","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82067,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1759,"USUBJID":"PSIVISSIG0002_1759","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93908,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1760,"USUBJID":"PSIVISSIG0002_1760","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49418,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1761,"USUBJID":"PSIVISSIG0002_1761","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82957,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1762,"USUBJID":"PSIVISSIG0002_1762","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61807,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1763,"USUBJID":"PSIVISSIG0002_1763","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.7269,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1764,"USUBJID":"PSIVISSIG0002_1764","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48939,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1765,"USUBJID":"PSIVISSIG0002_1765","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49008,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1766,"USUBJID":"PSIVISSIG0002_1766","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.38877,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1767,"USUBJID":"PSIVISSIG0002_1767","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.61054,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1768,"USUBJID":"PSIVISSIG0002_1768","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82409,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1769,"USUBJID":"PSIVISSIG0002_1769","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84805,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1770,"USUBJID":"PSIVISSIG0002_1770","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.577,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1771,"USUBJID":"PSIVISSIG0002_1771","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61807,"CNSR":1,"EVNTDESC":"Second next-line therapy initiated","CNSDTDSC":"Censored at the end date of the next-line therapy","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1772,"USUBJID":"PSIVISSIG0002_1772","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49008,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1773,"USUBJID":"PSIVISSIG0002_1773","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66804,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1774,"USUBJID":"PSIVISSIG0002_1774","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.88364,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1775,"USUBJID":"PSIVISSIG0002_1775","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.18275,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1776,"USUBJID":"PSIVISSIG0002_1776","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.41342,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1777,"USUBJID":"PSIVISSIG0002_1777","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0616,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1778,"USUBJID":"PSIVISSIG0002_1778","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.5551,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1779,"USUBJID":"PSIVISSIG0002_1779","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36003,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1780,"USUBJID":"PSIVISSIG0002_1780","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57974,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1781,"USUBJID":"PSIVISSIG0002_1781","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82067,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1782,"USUBJID":"PSIVISSIG0002_1782","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.1013,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1783,"USUBJID":"PSIVISSIG0002_1783","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.67009,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1784,"USUBJID":"PSIVISSIG0002_1784","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4757,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1785,"USUBJID":"PSIVISSIG0002_1785","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.75154,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1786,"USUBJID":"PSIVISSIG0002_1786","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.31211,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1787,"USUBJID":"PSIVISSIG0002_1787","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.46407,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1788,"USUBJID":"PSIVISSIG0002_1788","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.30869,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1789,"USUBJID":"PSIVISSIG0002_1789","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.8104,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1790,"USUBJID":"PSIVISSIG0002_1790","AGE":38,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.63244,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1791,"USUBJID":"PSIVISSIG0002_1791","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51129,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1792,"USUBJID":"PSIVISSIG0002_1792","AGE":81,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.78439,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1793,"USUBJID":"PSIVISSIG0002_1793","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96235,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1794,"USUBJID":"PSIVISSIG0002_1794","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.73169,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1795,"USUBJID":"PSIVISSIG0002_1795","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.3614,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1796,"USUBJID":"PSIVISSIG0002_1796","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78303,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1797,"USUBJID":"PSIVISSIG0002_1797","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.00205,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1798,"USUBJID":"PSIVISSIG0002_1798","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.72211,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1799,"USUBJID":"PSIVISSIG0002_1799","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7885,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1800,"USUBJID":"PSIVISSIG0002_1800","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48118,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1801,"USUBJID":"PSIVISSIG0002_1801","AGE":82,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.77481,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1802,"USUBJID":"PSIVISSIG0002_1802","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.11567,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1803,"USUBJID":"PSIVISSIG0002_1803","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97604,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1804,"USUBJID":"PSIVISSIG0002_1804","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04517,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1805,"USUBJID":"PSIVISSIG0002_1805","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79124,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1806,"USUBJID":"PSIVISSIG0002_1806","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.77618,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1807,"USUBJID":"PSIVISSIG0002_1807","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08419,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1808,"USUBJID":"PSIVISSIG0002_1808","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62149,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1809,"USUBJID":"PSIVISSIG0002_1809","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.24709,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1810,"USUBJID":"PSIVISSIG0002_1810","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.44559,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1811,"USUBJID":"PSIVISSIG0002_1811","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.83641,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1812,"USUBJID":"PSIVISSIG0002_1812","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.04175,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1813,"USUBJID":"PSIVISSIG0002_1813","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.12731,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1814,"USUBJID":"PSIVISSIG0002_1814","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35318,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1815,"USUBJID":"PSIVISSIG0002_1815","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.58248,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1816,"USUBJID":"PSIVISSIG0002_1816","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82067,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1817,"USUBJID":"PSIVISSIG0002_1817","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.32786,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1818,"USUBJID":"PSIVISSIG0002_1818","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.95414,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1819,"USUBJID":"PSIVISSIG0002_1819","AGE":81,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65435,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1820,"USUBJID":"PSIVISSIG0002_1820","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.96646,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1821,"USUBJID":"PSIVISSIG0002_1821","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.59069,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1822,"USUBJID":"PSIVISSIG0002_1822","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.89185,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1823,"USUBJID":"PSIVISSIG0002_1823","AGE":85,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.1013,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1824,"USUBJID":"PSIVISSIG0002_1824","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.60027,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1825,"USUBJID":"PSIVISSIG0002_1825","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.8809,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1826,"USUBJID":"PSIVISSIG0002_1826","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.61602,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1827,"USUBJID":"PSIVISSIG0002_1827","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.50308,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1828,"USUBJID":"PSIVISSIG0002_1828","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.91923,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1829,"USUBJID":"PSIVISSIG0002_1829","AGE":47,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52567,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1830,"USUBJID":"PSIVISSIG0002_1830","AGE":53,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51745,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1831,"USUBJID":"PSIVISSIG0002_1831","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.94593,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1832,"USUBJID":"PSIVISSIG0002_1832","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82067,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1833,"USUBJID":"PSIVISSIG0002_1833","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78029,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1834,"USUBJID":"PSIVISSIG0002_1834","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.62423,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1835,"USUBJID":"PSIVISSIG0002_1835","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70568,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1836,"USUBJID":"PSIVISSIG0002_1836","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.18412,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1837,"USUBJID":"PSIVISSIG0002_1837","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04381,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1838,"USUBJID":"PSIVISSIG0002_1838","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49418,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1839,"USUBJID":"PSIVISSIG0002_1839","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.99795,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1840,"USUBJID":"PSIVISSIG0002_1840","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70568,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1841,"USUBJID":"PSIVISSIG0002_1841","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.00274,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1842,"USUBJID":"PSIVISSIG0002_1842","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.5989,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1843,"USUBJID":"PSIVISSIG0002_1843","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84257,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1844,"USUBJID":"PSIVISSIG0002_1844","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64339,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1845,"USUBJID":"PSIVISSIG0002_1845","AGE":25,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19576,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1846,"USUBJID":"PSIVISSIG0002_1846","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.1629,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1847,"USUBJID":"PSIVISSIG0002_1847","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.86858,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1848,"USUBJID":"PSIVISSIG0002_1848","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00137,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1849,"USUBJID":"PSIVISSIG0002_1849","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.37782,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1850,"USUBJID":"PSIVISSIG0002_1850","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10883,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1851,"USUBJID":"PSIVISSIG0002_1851","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.58248,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1852,"USUBJID":"PSIVISSIG0002_1852","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.77755,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1853,"USUBJID":"PSIVISSIG0002_1853","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.01985,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1854,"USUBJID":"PSIVISSIG0002_1854","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.19097,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1855,"USUBJID":"PSIVISSIG0002_1855","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.45654,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1856,"USUBJID":"PSIVISSIG0002_1856","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.15811,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1857,"USUBJID":"PSIVISSIG0002_1857","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04517,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1858,"USUBJID":"PSIVISSIG0002_1858","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19302,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1859,"USUBJID":"PSIVISSIG0002_1859","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28953,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1860,"USUBJID":"PSIVISSIG0002_1860","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48665,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1861,"USUBJID":"PSIVISSIG0002_1861","AGE":40,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51198,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1862,"USUBJID":"PSIVISSIG0002_1862","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.29774,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1863,"USUBJID":"PSIVISSIG0002_1863","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.16085,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1864,"USUBJID":"PSIVISSIG0002_1864","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.71937,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1865,"USUBJID":"PSIVISSIG0002_1865","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.7707,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1866,"USUBJID":"PSIVISSIG0002_1866","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.846,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1867,"USUBJID":"PSIVISSIG0002_1867","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.91718,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1868,"USUBJID":"PSIVISSIG0002_1868","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.64339,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1869,"USUBJID":"PSIVISSIG0002_1869","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35592,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1870,"USUBJID":"PSIVISSIG0002_1870","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7091,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1871,"USUBJID":"PSIVISSIG0002_1871","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.40726,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1872,"USUBJID":"PSIVISSIG0002_1872","AGE":84,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.42574,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1873,"USUBJID":"PSIVISSIG0002_1873","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.05886,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1874,"USUBJID":"PSIVISSIG0002_1874","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.3744,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1875,"USUBJID":"PSIVISSIG0002_1875","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.90007,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1876,"USUBJID":"PSIVISSIG0002_1876","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.86516,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1877,"USUBJID":"PSIVISSIG0002_1877","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.86653,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1878,"USUBJID":"PSIVISSIG0002_1878","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47775,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1879,"USUBJID":"PSIVISSIG0002_1879","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.23888,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1880,"USUBJID":"PSIVISSIG0002_1880","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.38946,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1881,"USUBJID":"PSIVISSIG0002_1881","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.4141,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1882,"USUBJID":"PSIVISSIG0002_1882","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.09377,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1883,"USUBJID":"PSIVISSIG0002_1883","AGE":35,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.8152,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1884,"USUBJID":"PSIVISSIG0002_1884","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67351,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1885,"USUBJID":"PSIVISSIG0002_1885","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.60164,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1886,"USUBJID":"PSIVISSIG0002_1886","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.8104,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1887,"USUBJID":"PSIVISSIG0002_1887","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.36824,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1888,"USUBJID":"PSIVISSIG0002_1888","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.71732,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1889,"USUBJID":"PSIVISSIG0002_1889","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08145,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1890,"USUBJID":"PSIVISSIG0002_1890","AGE":80,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.74196,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1891,"USUBJID":"PSIVISSIG0002_1891","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.60849,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1892,"USUBJID":"PSIVISSIG0002_1892","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48118,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1893,"USUBJID":"PSIVISSIG0002_1893","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.56263,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1894,"USUBJID":"PSIVISSIG0002_1894","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.23614,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1895,"USUBJID":"PSIVISSIG0002_1895","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.90281,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1896,"USUBJID":"PSIVISSIG0002_1896","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08145,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1897,"USUBJID":"PSIVISSIG0002_1897","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56331,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1898,"USUBJID":"PSIVISSIG0002_1898","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.16222,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1899,"USUBJID":"PSIVISSIG0002_1899","AGE":84,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.42574,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1900,"USUBJID":"PSIVISSIG0002_1900","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.48665,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1901,"USUBJID":"PSIVISSIG0002_1901","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.95962,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1902,"USUBJID":"PSIVISSIG0002_1902","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82957,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1903,"USUBJID":"PSIVISSIG0002_1903","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.2731,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1904,"USUBJID":"PSIVISSIG0002_1904","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49692,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1905,"USUBJID":"PSIVISSIG0002_1905","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.70431,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1906,"USUBJID":"PSIVISSIG0002_1906","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.47365,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1907,"USUBJID":"PSIVISSIG0002_1907","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.18207,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1908,"USUBJID":"PSIVISSIG0002_1908","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.46407,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1909,"USUBJID":"PSIVISSIG0002_1909","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4976,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1910,"USUBJID":"PSIVISSIG0002_1910","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.56194,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1911,"USUBJID":"PSIVISSIG0002_1911","AGE":45,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.95277,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1912,"USUBJID":"PSIVISSIG0002_1912","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.18686,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1913,"USUBJID":"PSIVISSIG0002_1913","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.19439,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1914,"USUBJID":"PSIVISSIG0002_1914","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.987,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1915,"USUBJID":"PSIVISSIG0002_1915","AGE":40,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.47912,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1916,"USUBJID":"PSIVISSIG0002_1916","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97467,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1917,"USUBJID":"PSIVISSIG0002_1917","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.84257,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1918,"USUBJID":"PSIVISSIG0002_1918","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.78439,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1919,"USUBJID":"PSIVISSIG0002_1919","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.20739,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1920,"USUBJID":"PSIVISSIG0002_1920","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.71595,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1921,"USUBJID":"PSIVISSIG0002_1921","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.18891,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1922,"USUBJID":"PSIVISSIG0002_1922","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.8282,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1923,"USUBJID":"PSIVISSIG0002_1923","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.07598,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1924,"USUBJID":"PSIVISSIG0002_1924","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.5243,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1925,"USUBJID":"PSIVISSIG0002_1925","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.59069,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1926,"USUBJID":"PSIVISSIG0002_1926","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.24162,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1927,"USUBJID":"PSIVISSIG0002_1927","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.99247,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1928,"USUBJID":"PSIVISSIG0002_1928","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47775,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1929,"USUBJID":"PSIVISSIG0002_1929","AGE":79,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.40315,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1930,"USUBJID":"PSIVISSIG0002_1930","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.12936,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1931,"USUBJID":"PSIVISSIG0002_1931","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.3128,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1932,"USUBJID":"PSIVISSIG0002_1932","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.13279,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1933,"USUBJID":"PSIVISSIG0002_1933","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47502,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1934,"USUBJID":"PSIVISSIG0002_1934","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.4319,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1935,"USUBJID":"PSIVISSIG0002_1935","AGE":84,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.38056,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1936,"USUBJID":"PSIVISSIG0002_1936","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.04517,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1937,"USUBJID":"PSIVISSIG0002_1937","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.52841,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1938,"USUBJID":"PSIVISSIG0002_1938","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.98836,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1939,"USUBJID":"PSIVISSIG0002_1939","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.28063,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1940,"USUBJID":"PSIVISSIG0002_1940","AGE":48,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.10951,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1941,"USUBJID":"PSIVISSIG0002_1941","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96509,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1942,"USUBJID":"PSIVISSIG0002_1942","AGE":85,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.09035,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1943,"USUBJID":"PSIVISSIG0002_1943","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.97741,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1944,"USUBJID":"PSIVISSIG0002_1944","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66256,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1945,"USUBJID":"PSIVISSIG0002_1945","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.0794,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1946,"USUBJID":"PSIVISSIG0002_1946","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.59959,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1947,"USUBJID":"PSIVISSIG0002_1947","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49418,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1948,"USUBJID":"PSIVISSIG0002_1948","AGE":49,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93634,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1949,"USUBJID":"PSIVISSIG0002_1949","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.18754,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1950,"USUBJID":"PSIVISSIG0002_1950","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81725,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1951,"USUBJID":"PSIVISSIG0002_1951","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56605,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1952,"USUBJID":"PSIVISSIG0002_1952","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.79124,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1953,"USUBJID":"PSIVISSIG0002_1953","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.67009,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1954,"USUBJID":"PSIVISSIG0002_1954","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49555,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1955,"USUBJID":"PSIVISSIG0002_1955","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.01506,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1956,"USUBJID":"PSIVISSIG0002_1956","AGE":78,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.295,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1957,"USUBJID":"PSIVISSIG0002_1957","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95825,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1958,"USUBJID":"PSIVISSIG0002_1958","AGE":78,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.74127,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1959,"USUBJID":"PSIVISSIG0002_1959","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65708,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1960,"USUBJID":"PSIVISSIG0002_1960","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.4846,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1961,"USUBJID":"PSIVISSIG0002_1961","AGE":68,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.94661,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1962,"USUBJID":"PSIVISSIG0002_1962","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69815,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1963,"USUBJID":"PSIVISSIG0002_1963","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47775,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1964,"USUBJID":"PSIVISSIG0002_1964","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49144,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1965,"USUBJID":"PSIVISSIG0002_1965","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6564,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1966,"USUBJID":"PSIVISSIG0002_1966","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.16016,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1967,"USUBJID":"PSIVISSIG0002_1967","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.22724,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1968,"USUBJID":"PSIVISSIG0002_1968","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.6783,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1969,"USUBJID":"PSIVISSIG0002_1969","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.75359,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1970,"USUBJID":"PSIVISSIG0002_1970","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.84873,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1971,"USUBJID":"PSIVISSIG0002_1971","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.77618,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1972,"USUBJID":"PSIVISSIG0002_1972","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.00137,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1973,"USUBJID":"PSIVISSIG0002_1973","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.92471,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1974,"USUBJID":"PSIVISSIG0002_1974","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.96988,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1975,"USUBJID":"PSIVISSIG0002_1975","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.39904,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1976,"USUBJID":"PSIVISSIG0002_1976","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.19028,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1977,"USUBJID":"PSIVISSIG0002_1977","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28679,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1978,"USUBJID":"PSIVISSIG0002_1978","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.66393,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1979,"USUBJID":"PSIVISSIG0002_1979","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.83504,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1980,"USUBJID":"PSIVISSIG0002_1980","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51951,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1981,"USUBJID":"PSIVISSIG0002_1981","AGE":75,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.5332,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1982,"USUBJID":"PSIVISSIG0002_1982","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.63997,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1983,"USUBJID":"PSIVISSIG0002_1983","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.8104,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1984,"USUBJID":"PSIVISSIG0002_1984","AGE":38,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.65708,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1985,"USUBJID":"PSIVISSIG0002_1985","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.16153,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1986,"USUBJID":"PSIVISSIG0002_1986","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.52361,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1987,"USUBJID":"PSIVISSIG0002_1987","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.09993,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1988,"USUBJID":"PSIVISSIG0002_1988","AGE":53,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.3525,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1989,"USUBJID":"PSIVISSIG0002_1989","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.32786,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1990,"USUBJID":"PSIVISSIG0002_1990","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.72348,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1991,"USUBJID":"PSIVISSIG0002_1991","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.74743,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1992,"USUBJID":"PSIVISSIG0002_1992","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.78303,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1993,"USUBJID":"PSIVISSIG0002_1993","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.88296,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1994,"USUBJID":"PSIVISSIG0002_1994","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.49966,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1995,"USUBJID":"PSIVISSIG0002_1995","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.29706,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1996,"USUBJID":"PSIVISSIG0002_1996","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.96235,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1997,"USUBJID":"PSIVISSIG0002_1997","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.12731,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1998,"USUBJID":"PSIVISSIG0002_1998","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.81451,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":1999,"USUBJID":"PSIVISSIG0002_1999","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.53114,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2000,"USUBJID":"PSIVISSIG0002_2000","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.63176,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2001,"USUBJID":"PSIVISSIG0002_2001","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.75975,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2002,"USUBJID":"PSIVISSIG0002_2002","AGE":52,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.36071,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2003,"USUBJID":"PSIVISSIG0002_2003","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.31143,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2004,"USUBJID":"PSIVISSIG0002_2004","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.98015,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2005,"USUBJID":"PSIVISSIG0002_2005","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.73374,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2006,"USUBJID":"PSIVISSIG0002_2006","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66804,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2007,"USUBJID":"PSIVISSIG0002_2007","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.94456,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2008,"USUBJID":"PSIVISSIG0002_2008","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.57769,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2009,"USUBJID":"PSIVISSIG0002_2009","AGE":48,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.83915,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2010,"USUBJID":"PSIVISSIG0002_2010","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.77139,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2011,"USUBJID":"PSIVISSIG0002_2011","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.15537,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2012,"USUBJID":"PSIVISSIG0002_2012","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.23888,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2013,"USUBJID":"PSIVISSIG0002_2013","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.00479,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2014,"USUBJID":"PSIVISSIG0002_2014","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.31896,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2015,"USUBJID":"PSIVISSIG0002_2015","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.89733,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2016,"USUBJID":"PSIVISSIG0002_2016","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.51403,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2017,"USUBJID":"PSIVISSIG0002_2017","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66804,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2018,"USUBJID":"PSIVISSIG0002_2018","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.2115,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2019,"USUBJID":"PSIVISSIG0002_2019","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.1191,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2020,"USUBJID":"PSIVISSIG0002_2020","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.11225,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2021,"USUBJID":"PSIVISSIG0002_2021","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.75838,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2022,"USUBJID":"PSIVISSIG0002_2022","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.20055,"CNSR":1,"EVNTDESC":"Second next-line therapy initiated","CNSDTDSC":"Censored at the end date of the next-line therapy","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2023,"USUBJID":"PSIVISSIG0002_2023","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54689,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2024,"USUBJID":"PSIVISSIG0002_2024","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.68309,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2025,"USUBJID":"PSIVISSIG0002_2025","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.08761,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2026,"USUBJID":"PSIVISSIG0002_2026","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42094,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2027,"USUBJID":"PSIVISSIG0002_2027","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.40794,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2028,"USUBJID":"PSIVISSIG0002_2028","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.59274,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2029,"USUBJID":"PSIVISSIG0002_2029","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.86585,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2030,"USUBJID":"PSIVISSIG0002_2030","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.21013,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2031,"USUBJID":"PSIVISSIG0002_2031","AGE":39,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10609,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2032,"USUBJID":"PSIVISSIG0002_2032","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.1321,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2033,"USUBJID":"PSIVISSIG0002_2033","AGE":73,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.78508,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2034,"USUBJID":"PSIVISSIG0002_2034","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.70089,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2035,"USUBJID":"PSIVISSIG0002_2035","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.53388,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2036,"USUBJID":"PSIVISSIG0002_2036","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.42437,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2037,"USUBJID":"PSIVISSIG0002_2037","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.79261,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2038,"USUBJID":"PSIVISSIG0002_2038","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.98152,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2039,"USUBJID":"PSIVISSIG0002_2039","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.26762,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2040,"USUBJID":"PSIVISSIG0002_2040","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.56263,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2041,"USUBJID":"PSIVISSIG0002_2041","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.97057,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2042,"USUBJID":"PSIVISSIG0002_2042","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.42642,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2043,"USUBJID":"PSIVISSIG0002_2043","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.38741,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2044,"USUBJID":"PSIVISSIG0002_2044","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.59206,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2045,"USUBJID":"PSIVISSIG0002_2045","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.60027,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2046,"USUBJID":"PSIVISSIG0002_2046","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.84942,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2047,"USUBJID":"PSIVISSIG0002_2047","AGE":43,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.16701,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2048,"USUBJID":"PSIVISSIG0002_2048","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.04654,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2049,"USUBJID":"PSIVISSIG0002_2049","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72005,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2050,"USUBJID":"PSIVISSIG0002_2050","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.35866,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2051,"USUBJID":"PSIVISSIG0002_2051","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.61054,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2052,"USUBJID":"PSIVISSIG0002_2052","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":5.26489,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2053,"USUBJID":"PSIVISSIG0002_2053","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.79603,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2054,"USUBJID":"PSIVISSIG0002_2054","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0616,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2055,"USUBJID":"PSIVISSIG0002_2055","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.48734,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2056,"USUBJID":"PSIVISSIG0002_2056","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47228,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2057,"USUBJID":"PSIVISSIG0002_2057","AGE":41,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.37714,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2058,"USUBJID":"PSIVISSIG0002_2058","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.59069,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2059,"USUBJID":"PSIVISSIG0002_2059","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.03491,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2060,"USUBJID":"PSIVISSIG0002_2060","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.53525,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2061,"USUBJID":"PSIVISSIG0002_2061","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.14921,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2062,"USUBJID":"PSIVISSIG0002_2062","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.82341,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2063,"USUBJID":"PSIVISSIG0002_2063","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70842,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2064,"USUBJID":"PSIVISSIG0002_2064","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.1896,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2065,"USUBJID":"PSIVISSIG0002_2065","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.13689,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2066,"USUBJID":"PSIVISSIG0002_2066","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.00274,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2067,"USUBJID":"PSIVISSIG0002_2067","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.08898,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2068,"USUBJID":"PSIVISSIG0002_2068","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.37509,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2069,"USUBJID":"PSIVISSIG0002_2069","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.72553,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2070,"USUBJID":"PSIVISSIG0002_2070","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.89938,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2071,"USUBJID":"PSIVISSIG0002_2071","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02875,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2072,"USUBJID":"PSIVISSIG0002_2072","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.4449,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2073,"USUBJID":"PSIVISSIG0002_2073","AGE":59,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.05133,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2074,"USUBJID":"PSIVISSIG0002_2074","AGE":79,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.75496,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2075,"USUBJID":"PSIVISSIG0002_2075","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.0486,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2076,"USUBJID":"PSIVISSIG0002_2076","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.26968,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2077,"USUBJID":"PSIVISSIG0002_2077","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.22656,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2078,"USUBJID":"PSIVISSIG0002_2078","AGE":35,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.80698,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2079,"USUBJID":"PSIVISSIG0002_2079","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.57769,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2080,"USUBJID":"PSIVISSIG0002_2080","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.70431,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2081,"USUBJID":"PSIVISSIG0002_2081","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.22587,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2082,"USUBJID":"PSIVISSIG0002_2082","AGE":60,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.98289,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2083,"USUBJID":"PSIVISSIG0002_2083","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.62355,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2084,"USUBJID":"PSIVISSIG0002_2084","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.8679,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2085,"USUBJID":"PSIVISSIG0002_2085","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.7399,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"ADVERSE EVENT"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2086,"USUBJID":"PSIVISSIG0002_2086","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.42163,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2087,"USUBJID":"PSIVISSIG0002_2087","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82136,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2088,"USUBJID":"PSIVISSIG0002_2088","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.17454,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2089,"USUBJID":"PSIVISSIG0002_2089","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.02669,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2090,"USUBJID":"PSIVISSIG0002_2090","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.87269,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2091,"USUBJID":"PSIVISSIG0002_2091","AGE":44,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.6653,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2092,"USUBJID":"PSIVISSIG0002_2092","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.42984,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2093,"USUBJID":"PSIVISSIG0002_2093","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.66804,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2094,"USUBJID":"PSIVISSIG0002_2094","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.05407,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2095,"USUBJID":"PSIVISSIG0002_2095","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.7091,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2096,"USUBJID":"PSIVISSIG0002_2096","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.72621,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2097,"USUBJID":"PSIVISSIG0002_2097","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28405,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2098,"USUBJID":"PSIVISSIG0002_2098","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.38604,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2099,"USUBJID":"PSIVISSIG0002_2099","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80767,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2100,"USUBJID":"PSIVISSIG0002_2100","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70021,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2101,"USUBJID":"PSIVISSIG0002_2101","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.03696,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2102,"USUBJID":"PSIVISSIG0002_2102","AGE":87,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.15469,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2103,"USUBJID":"PSIVISSIG0002_2103","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.83778,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2104,"USUBJID":"PSIVISSIG0002_2104","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56057,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2105,"USUBJID":"PSIVISSIG0002_2105","AGE":60,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.01232,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2106,"USUBJID":"PSIVISSIG0002_2106","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.08966,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2107,"USUBJID":"PSIVISSIG0002_2107","AGE":56,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.859,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2108,"USUBJID":"PSIVISSIG0002_2108","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.9514,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2109,"USUBJID":"PSIVISSIG0002_2109","AGE":37,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68104,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2110,"USUBJID":"PSIVISSIG0002_2110","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02053,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2111,"USUBJID":"PSIVISSIG0002_2111","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.63997,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2112,"USUBJID":"PSIVISSIG0002_2112","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.51745,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2113,"USUBJID":"PSIVISSIG0002_2113","AGE":62,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85147,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2114,"USUBJID":"PSIVISSIG0002_2114","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.1848,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2115,"USUBJID":"PSIVISSIG0002_2115","AGE":76,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.74127,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2116,"USUBJID":"PSIVISSIG0002_2116","AGE":48,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.45175,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2117,"USUBJID":"PSIVISSIG0002_2117","AGE":67,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.49829,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2118,"USUBJID":"PSIVISSIG0002_2118","AGE":73,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.20055,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2119,"USUBJID":"PSIVISSIG0002_2119","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.07118,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2120,"USUBJID":"PSIVISSIG0002_2120","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.48049,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2121,"USUBJID":"PSIVISSIG0002_2121","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.02875,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2122,"USUBJID":"PSIVISSIG0002_2122","AGE":72,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56331,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2123,"USUBJID":"PSIVISSIG0002_2123","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.69815,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2124,"USUBJID":"PSIVISSIG0002_2124","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.89185,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2125,"USUBJID":"PSIVISSIG0002_2125","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.23477,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2126,"USUBJID":"PSIVISSIG0002_2126","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.84394,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2127,"USUBJID":"PSIVISSIG0002_2127","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.76797,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2128,"USUBJID":"PSIVISSIG0002_2128","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.32444,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2129,"USUBJID":"PSIVISSIG0002_2129","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.18823,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2130,"USUBJID":"PSIVISSIG0002_2130","AGE":58,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.48871,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2131,"USUBJID":"PSIVISSIG0002_2131","AGE":63,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.81793,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2132,"USUBJID":"PSIVISSIG0002_2132","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":4.61875,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2133,"USUBJID":"PSIVISSIG0002_2133","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.18617,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2134,"USUBJID":"PSIVISSIG0002_2134","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.31622,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2135,"USUBJID":"PSIVISSIG0002_2135","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.57084,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2136,"USUBJID":"PSIVISSIG0002_2136","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.22587,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2137,"USUBJID":"PSIVISSIG0002_2137","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56331,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2138,"USUBJID":"PSIVISSIG0002_2138","AGE":56,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.06434,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2139,"USUBJID":"PSIVISSIG0002_2139","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.3128,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2140,"USUBJID":"PSIVISSIG0002_2140","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.68925,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2141,"USUBJID":"PSIVISSIG0002_2141","AGE":57,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56057,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2142,"USUBJID":"PSIVISSIG0002_2142","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.97262,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2143,"USUBJID":"PSIVISSIG0002_2143","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.13826,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2144,"USUBJID":"PSIVISSIG0002_2144","AGE":66,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.95962,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2145,"USUBJID":"PSIVISSIG0002_2145","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.06708,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2146,"USUBJID":"PSIVISSIG0002_2146","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.70021,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2147,"USUBJID":"PSIVISSIG0002_2147","AGE":58,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.46817,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2148,"USUBJID":"PSIVISSIG0002_2148","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.98289,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2149,"USUBJID":"PSIVISSIG0002_2149","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.26078,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2150,"USUBJID":"PSIVISSIG0002_2150","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.67077,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2151,"USUBJID":"PSIVISSIG0002_2151","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.94319,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2152,"USUBJID":"PSIVISSIG0002_2152","AGE":59,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.85763,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2153,"USUBJID":"PSIVISSIG0002_2153","AGE":64,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82136,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2154,"USUBJID":"PSIVISSIG0002_2154","AGE":55,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.05202,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2155,"USUBJID":"PSIVISSIG0002_2155","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.94045,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2156,"USUBJID":"PSIVISSIG0002_2156","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.42437,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2157,"USUBJID":"PSIVISSIG0002_2157","AGE":44,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.12252,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2158,"USUBJID":"PSIVISSIG0002_2158","AGE":61,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.10335,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2159,"USUBJID":"PSIVISSIG0002_2159","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.20945,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2160,"USUBJID":"PSIVISSIG0002_2160","AGE":71,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.43943,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2161,"USUBJID":"PSIVISSIG0002_2161","AGE":52,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.19713,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROTOCOL DEVIATION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2162,"USUBJID":"PSIVISSIG0002_2162","AGE":69,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.77481,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2163,"USUBJID":"PSIVISSIG0002_2163","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.25394,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2164,"USUBJID":"PSIVISSIG0002_2164","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.30527,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2165,"USUBJID":"PSIVISSIG0002_2165","AGE":67,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.55647,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2166,"USUBJID":"PSIVISSIG0002_2166","AGE":80,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.20808,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"SUBJECT/GUARDIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2167,"USUBJID":"PSIVISSIG0002_2167","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.54141,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2168,"USUBJID":"PSIVISSIG0002_2168","AGE":54,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.57153,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2169,"USUBJID":"PSIVISSIG0002_2169","AGE":76,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.47228,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"DEATH"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2170,"USUBJID":"PSIVISSIG0002_2170","AGE":72,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.92197,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2171,"USUBJID":"PSIVISSIG0002_2171","AGE":77,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.39562,"CNSR":1,"EVNTDESC":"Lost to follow-up","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2172,"USUBJID":"PSIVISSIG0002_2172","AGE":68,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.76797,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PHYSICIAN DECISION"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2173,"USUBJID":"PSIVISSIG0002_2173","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.96372,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2174,"USUBJID":"PSIVISSIG0002_2174","AGE":66,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.36893,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2175,"USUBJID":"PSIVISSIG0002_2175","AGE":55,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.0178,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2176,"USUBJID":"PSIVISSIG0002_2176","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.76797,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2177,"USUBJID":"PSIVISSIG0002_2177","AGE":75,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.87337,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2178,"USUBJID":"PSIVISSIG0002_2178","AGE":45,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.7885,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2179,"USUBJID":"PSIVISSIG0002_2179","AGE":54,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.30253,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2180,"USUBJID":"PSIVISSIG0002_2180","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.82409,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2181,"USUBJID":"PSIVISSIG0002_2181","AGE":74,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.85969,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2182,"USUBJID":"PSIVISSIG0002_2182","AGE":63,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.80219,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2183,"USUBJID":"PSIVISSIG0002_2183","AGE":69,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"PRIOR USE","STR02N":1,"STR02L":"Prior Radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.8104,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2184,"USUBJID":"PSIVISSIG0002_2184","AGE":71,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.56605,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2185,"USUBJID":"PSIVISSIG0002_2185","AGE":65,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.71253,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2186,"USUBJID":"PSIVISSIG0002_2186","AGE":70,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.68309,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2187,"USUBJID":"PSIVISSIG0002_2187","AGE":46,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.59138,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2188,"USUBJID":"PSIVISSIG0002_2188","AGE":50,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.76591,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2189,"USUBJID":"PSIVISSIG0002_2189","AGE":62,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.61123,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2190,"USUBJID":"PSIVISSIG0002_2190","AGE":70,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.09035,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2191,"USUBJID":"PSIVISSIG0002_2191","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":3.81109,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2192,"USUBJID":"PSIVISSIG0002_2192","AGE":88,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.95277,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2193,"USUBJID":"PSIVISSIG0002_2193","AGE":74,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.61807,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2194,"USUBJID":"PSIVISSIG0002_2194","AGE":64,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.99316,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2195,"USUBJID":"PSIVISSIG0002_2195","AGE":51,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 12 week -> vismab 34 weeks","TRT01PN":3,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.93087,"CNSR":1,"EVNTDESC":"No next-line therapy initiated","CNSDTDSC":"Censored at the last contact date"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2196,"USUBJID":"PSIVISSIG0002_2196","AGE":57,"STR01":"Positive","STR01N":1,"STR01L":"Hormone receptor positive","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab + vismab 52 weeks","TRT01PN":4,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.28131,"CNSR":0,"EVNTDESC":"PD","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2197,"USUBJID":"PSIVISSIG0002_2197","AGE":61,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":1.76318,"CNSR":1,"EVNTDESC":"Ongoing on first next-line therapy","CNSDTDSC":"Censored at the last contact date","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2198,"USUBJID":"PSIVISSIG0002_2198","AGE":65,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"tablemab x 52 weeks","TRT01PN":1,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":2.34634,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}
{"STUDYID":"PSIVISSIG0002","SUBJID":2199,"USUBJID":"PSIVISSIG0002_2199","AGE":50,"STR01":"Negative","STR01N":2,"STR01L":"Hormone receptor negative","STR02":"NO PRIOR USE","STR02N":2,"STR02L":"No prior radiotherapy","TRT01P":"vismab x 52 weeks","TRT01PN":2,"PARAM":"Progression-free survival (years)","PARAMCD":"PFS","AVAL":0.44353,"CNSR":0,"EVNTDESC":"Death","DCTREAS":"PROGRESSIVE DISEASE"}